Halo Inc

NEW AWARD FOR $7,000,000 FUNDING ERW SURVEY AND CLEARANCE IN LAO PDR. POP OF 20 MONTHS. SEE TERMS AND CONDITIONS AND SOO BELOW.

HEALTH CENTER CLUSTER

CLUSTER MUNITION REMNANTS SURVEY OF SAVANNAKHET PROVINCE, LAOS

NEW AWARD OBLIGATING $2,000,000 IN COLOMBIA. SEE TERMS AND CONDITIONS AND STATEMENT OF OBJECTIVES BELOW.

NEW AWARD OBLIGATING $2,658,500 IN NADR-CWD FY19/20 IRAQ BILATERAL FUNDS. SOO AND TERMS AND CONDITIONS ATTACHED BELOW.

NEW AWARD FOR $2,500,000 SUPPORTING HMA IN CAMBODIA. POP OF 12 MONTHS. SEE SOO AND TERMS AND CONDITIONS BELOW.

APPROVES A NEW AWARD FOR $920,000. PRE AWARD COSTS APPROVED FROM NOV. 1ST 2022. PLEASE SEE THE AWARD PROVISIONS AND DOS TERMS AND CONDITIONS ATTACHED BELOW. - WEST BANK

NEW AWARD OBLIGATING $1.580.000 FOR NTS IN COLOMBIA. POP IS 12 MONTHS. PRE-AWARD COSTS NOT AUTHORIZED. SEE BELOW FOR TERMS AND CONDITIONS.

NEW AWARD WITH NO OPTION YEARS. AWARDING $990.164 IN FY17/18 SRI LANKA BILAT FUNDS. TERMS AND CONDITIONS ATTACHED.

NEW AWARD TO CONTINUE SPMWRA17GR1059 OBLIGATING $1,562,957 IN NADR CWD FY18/19 COLOMBIA FUNDS FOR 12 MONTH POP. TERMS AND CONDITIONS ARE ATTACHED.

HEALTH CENTER CLUSTER

DE-MINING

NEW AWARD OBLIGATING $4,400,000 IN CAMBODIA. SEE TERMS AND CONDITIONS AND STATEMENT OF OBJECTIVES BELOW.

NEW AWARD OBLIGATING $4,500,000 IN THE NORTHERN TRIANGLE. SEE TERMS AND CONDITIONS AND STATEMENT OF OBJECTIVES BELOW.

HUMANITARIAN MINECLEARANCE IN NORTH-WEST CAMBODIA

NEW AWARD OBLIGATING $2,250,000 IN NADR CWD ZIMBABWE BILAT. FUNDS. TERMS AND CONDITIONS AND SOO ATTACHED BELOW.

NEW AWARD OBLIGATING $2,800,000. SEE TERMS AND CONDITIONS AND SOO BELOW. - SRI LANKA

NEW AWARD OBLIGATING $4,000,000 IN SOMALIA. SEE TERMS AND CONDITIONS AND STATEMENT OF OBJECTIVES BELOW.

2014 SURVEY AND CLEARANCE OF SAVANNAKHET PROVINCE, LAOS

NEW AWARD OBLIGATING $1,000,000 IN FY19/20 NADR CWD FUNDS. POP OF 12 MONTHS. SEE TERMS AND CONDITIONS AND SOO BELOW

NEW AWARD OBLIGATING $2,500,000 IN NADR-CWD FY20/21 ANGOLA BILATERAL FUNDS. SEE TERMS AND CONDITIONS AND SOO BELOW.

HUMANITARIAN MINECLEARANCE IN ANGOLA

NEW AWARD OBLIGATING $1,094,000 TO HALO FOR WEST AFRICA. SEE TERMS AND CONDITIONS AND STATEMENT OF OBJECTIVES BELOW.

HUMANITARIAN MINE ACTION AND CONVENTIONAL MUNITIONS IN ANGOLA

NEW AWARD FOR $500,000 IN FY19/20 FUNDING FOR HMA IN LIBYA. POP OF 7 MONTHS. SEE TERMS AND CONDITIONS AND SOO BELOW.

HUMANITARIAN MINECLEARANCE IN ZIMBABWE

NEW AWARD TO COMPLETE CLUSTER MUNITION CLEARANCE OF SAVANNAKHET PROVINCE (INCREMENTALLY FUNDING $3.8M THIS ACTION). SEE THE SOO, AWARD PROVISIONS, AND DOS TERMS AND CONDITIONS BELOW. - LAOS

WEAPONS REMOVAL & ABATEMENT GRANTS PROJECT: MOZAMBIQUE

HUMANITARIAN MINE CLEARANCE PROGRAM

NEW AWARD TOTALING $4,800,000. ADD $3,300,000 IN FY20 NADR CWD FUNDS. INCR FUNDED. SEE TERMS AND CONDITIONS BELOW.

NEW AWARD OBLIGATING $2,256,557 FOR HMA IN ANGOLA FOR 12 MONTHS. SEE BELOW FOR AWARD PROVISIONS, TERMS AND CONDITIONS, AND STATEMENT OF OBJECTIVES.

NEW AWARD OBLIGATING $2,250,000.00 IN PAPAU NEW GUINEA FOR 24 MONTHS. SEE BELOW FOR AWARD PROVISIONS, TERMS AND CONDITIONS, AND STATEMENT OF OBJECTIVES.

NEW AWARD OF $1 MILLION (W/ 2 OPTION YEARS) FOR WEAPONS AND AMMUNITION DISPOSAL (WAD) IN SOMALIA. PLEASE FIND TERMS AND CONDITIONS BELOW.

NEW AWARD OF $1.201.585 WITH 3 OPTION YEARS FOR PSSM IN SOUTH CENTRAL SOMALIA. PLEASE FIND TERMS AND CONDITIONS BELOW.

MINECLEARANCE, EOD & SURVEY IN NORTHERN SRI LANKA

HUMANITARIAN MINE ACTION IN ANTIOQUIA, COLOMBIA

AMERICAN RESCUE PLAN ACT FUNDING FOR HEALTH CENTERS

NEW AWARD OBLIGATING $1,500,000. SEE TERMS AND CONDITIONS AND SOO BELOW. - MALAWI

NEW AWARD OBLIGATING $1,000,000. PLEASE SEE TERMS AND CONDITIONS AND SOO BELOW. - SOLOMON ISLANDS

NEW AWARD FOR $2,000,000 SUPPORTING HALO YEMEN. INCREMENTAL FUNDING OF $1,000,000. SEE TERMS AND CONDITIONS AND SOO BELOW.

NEW AWARD OBLIGATING $2,000,000 IN NADR CWD FY18/19 ANGOLA BILAT. FUNDS. POP 12 MONTHS. TERMS AND CONDITIONS BELOW.

UNEXPLODED ORDNANCE CLEARANCE IN SAVANNAKHET, LAOS

NEW AWARD OBLIGATING $4,000,000 IN SOMALIA. SEE TERMS AND CONDITIONS AND STATEMENT OF OBJECTIVES BELOW.

EMERGENCY SURVEY AND RESPONSE

ADVANCED MOLTEN GLASS FOR HEAT TRANSFER AND THERMAL ENERGY STORAGE

HUMANITARIAN MINECLEARANCE IN NORTHWEST CAMBODIA; MINES AND ERW POSING A THREAT TO CIVILIAN COMMUNITIES

MINE CLEARANCE PROGRAM

HMA

DEVELOPMENT OF A NOVEL HYALURONAN INHIBITOR FOR THE TREATMENT OF GROUP 3 PULMONARY HYPERTENSION (PH) - PROJECT SUMMARY GROUP 3 PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) IS A DEVASTATING DISEASE. PATIENTS WITH PH-ILD ARE PERPETUALLY SHORT OF BREATH AND OFTEN UNABLE TO WALK OR EVEN TO SPEAK IN FULL SENTENCES WITHOUT GASPING FOR AIR. CHARACTERIZED BY EXTENSIVE CHANGES IN THE EXTRACELLULAR MATRIX (ECM) AND THE VASCULATURE, PH IS OBSERVED IN UP TO 80% OF PATIENTS WITH ILD. THE SEVERITY OF PH IS THE MOST SIGNIFICANT PREDICTOR OF MORTALITY IN THESE PATIENTS, WHO HAVE AN AVERAGE LIFE EXPECTANCY OF ONLY 3-4 YEARS. EXISTING THERAPIES ARE OFTEN INEFFECTIVE, IN PART BECAUSE THEY TARGET INDIVIDUAL CELLS AND NOT THE TISSUE REMODELING THAT DRIVES THE DISEASE. WE DESPERATELY NEED NEW THERAPIES FOR PH-ILD. THERE IS STRONG EVIDENCE FROM IN VITRO AND ANIMAL MODELS OF PH THAT HYALURONAN (HA) DRIVES DISEASE PROGRESSION. HA, A PROMINENT COMPONENT OF THE ECM THAT FILLS THE SPACE BETWEEN CELLS IS OVEREXPRESSED IN THE LUNGS OF PATIENTS WITH PH AND IS ASSOCIATED WITH VASCULAR REMODELING, INFLAMMATION, AND FIBROSIS. GIVEN THE ROLE OF HA AND THE ECM IN PH-ILD PATHOGENESIS, HA IS AN ATTRACTIVE TARGET, ONE THAT IS CURRENTLY NOT TARGETED BY APPROVED DRUGS OR OTHER DRUGS IN DEVELOPMENT. 4-MU (4-METHYLUMBELLIFERONE) IS A SMALL MOLECULE INHIBITOR OF HA SYNTHESIS WITH THE POTENTIAL TO TREAT PH-ILD. 4- MU HAS SHOWN DRAMATIC PRECLINICAL EFFICACY IN MULTIPLE MOUSE MODELS OF PH. UNFORTUNATELY, 4-MU HAS POOR PHARMACOKINETICS, CHARACTERIZED BY EXTENSIVE 1ST PASS METABOLISM AND POOR BIOAVAILABILITY. WHILE 4-MU WORKS IN ANIMAL MODELS AT HIGH DOSAGES, WE NEED IMPROVED FORMULATIONS OF 4-MU TO BE ABLE TO TREAT HUMAN PH-ILD. WE HAVE DEVELOPED AN APPROACH TO THE FORMULATION OF 4-MU THAT ENHANCES SYSTEMIC DELIVERY, REDUCES 1ST PASS METABOLISM, AND PROMOTES BIOAVAILABILITY (H1614). OUR VISION IS THAT THIS FORMULATION WILL RESULT IN REDUCED DOSE BURDEN AND IMPROVED EFFICACY. TO ADVANCE OUR PROGRAM TO DELIVER A PROPRIETARY AGENT FOR PHASE 2 CLINICAL ASSESSMENT WE ARE PROPOSING THREE SPECIFIC AIMS FOR THIS GRANT APPLICATION: IN AIM 1 WE WILL MANUFACTURE 4-MU AS AN ORALLY DISINTEGRATING TABLET (ODT) USING PROPRIETARY ZYDIS® TECHNOLOGY AND EVALUATE THE PHARMACOKINETICS OF THE NEW FORMULATION IN AN ANIMAL MODEL. THEN, IN AIM 2 WE WILL PERFORM PRECLINICAL STUDIES TO IDENTIFY THE OPTIMAL DOSE OF 4-MU IN A RAT MODEL OF PH AND LUNG FIBROSIS AND TO DEFINE ITS TOXICOLOGY PROFILE TO CURRENT FDA STANDARDS. FINALLY, IN AIM 3 WE WILL VALIDATE ASSAYS TO QUANTITATE THE LEVELS OF 4-MU AND HA IN HUMAN SERUM, IN ORDER TO ENSURE COMPLIANCE WITH FDA STANDARDS TO SUPPORT THE PHASE 2 HUMAN CLINICAL TRIAL. COMPLETION OF THESE STUDIES WILL RESULT IN A PROPRIETARY, OPTIMIZED FORMULATION OF 4-MU READY FOR MANUFACTURING TO SUPPORT A PHASE 2 CLINICAL TRIAL IN PH-ILD (WHO GROUP 3). COMPLEMENTARY STUDIES OF TOXICOLOGY, PHARMACOLOGY, AND HUMAN PK ARE TO BE UNDERTAKEN DIRECTLY BY HALO BIOSCIENCES. THIS PROJECT HAS THE POTENTIAL TO TRANSFORM THE TREATMENT NOT ONLY OF PH-ILD, BUT OF OTHER DISEASES CHARACTERIZED BY INFLAMMATION AND FIBROSIS.

HUMANITARIAN MINECLEARANCE IN THE WEST BANK

WEAPONS AND AMMUNITION SAFETY AND SECURITY IN GUINEA BISSAU

HALOFILM: A SPRAY-ON, RE-CHARGEABLE, RE-APPLICABLE ANTIMICROBIAL COATING

GMP MANUFACTURING AND IND FILING OF IN-002, A POTENT INHALED MUCO-TRAPPING ANTIBODY THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS - TITLE: GMP MANUFACTURING AND IND FILING OF IN-002, A POTENT INHALED “MUCO-TRAPPING” ANTIBODY THERAPY FOR RESPIRATORY SYNCYTIAL VIRUS PROJECT SUMMARY (30 LINE LIMIT) RESPIRATORY SYNCYTIAL VIRUS (RSV) IS THE LEADING CAUSE OF VIRAL HOSPITALIZATION AND DEATH IN INFANTS AND YOUNG CHILDREN AND IS ALSO A MAJOR CAUSE OF RESPIRATORY ILLNESS IN IMMUNE COMPROMISED ADULTS AND THE ELDERLY. UNFORTUNATELY, THERE IS CURRENTLY EFFECTIVE THERAPY THAT CAN PREVENT RSV-HOSPITALIZATION. FOR THE MILLIONS INFECTED WITH RSV IN THE U.S. EVERY YEAR, THERE IS NO TREATMENT OPTION AVAILABLE ASIDE FROM SYMPTOM-MANAGEMENT. LIKE MANY RESPIRATORY PATHOGENS, RSV SPREADS IN THE LUNGS BY SHEDDING DAUGHTER VIRIONS FROM INFECTED CELLS EXCLUSIVELY BACK INTO THE AIRWAYS. FROM THERE, RSV MUST TRAVERSE THE AIRWAY MUCUS (AM) BEFORE INFECTING OTHER NEIGHBORING CELLS, REMAINING RESTRICTED TO THE AIRWAYS WITH LITTLE-TO-NO SYSTEMIC VIREMIA. THIS IMPORTANT MECHANISM OF SPREAD MAKES RSV DIFFICULT TO TARGET BY SYSTEMICALLY DOSED THERAPIES; THE ANTIVIRAL DRUGS NEED TO MAKE THEIR WAY TO THE AIRWAY MUCUS IN ORDER TO INACTIVATE VIRIONS AND HALT INFECTION. WE BELIEVE AN RSV-SPECIFIC, SAFE, AND EFFECTIVE ANTIVIRAL THERAPY THAT CAN BE INHALED DIRECTLY INTO THE RESPIRATORY TRACT USING A HAND-HELD DEVICE AT HOME WOULD PROVIDE A POWERFUL TREATMENT OPTION. TO MEET THIS GOAL, INHALON IS ADVANCING IN-002, A MAB THAT BINDS AND NEUTRALIZES RSV F PROTEIN WITH PICOMOLAR BINDING AFFINITY AND NEUTRALIZATION POTENCY, AND HAS MINIMAL RISKS OF VIRAL ESCAPE. IMPORTANTLY, IN ADDITION TO THE WELL-ESTABLISHED IGG FC EFFECTOR FUNCTIONS, IN-002 IS ALSO ENGINEERED TO POSSESS FC N-GLYCANS OPTIMIZED TO TRAP RSV IN AM. ONCE TRAPPED, RSV VIRIONS ARE QUICKLY PURGED FROM THE AIRWAYS VIA NATURAL MUCOCILIARY CLEARANCE MECHANISMS. WE HAVE FURTHER FORMULATED IN-002 TO BE STABLY NEBULIZED USING A PORTABLE VIBRATING MESH NEBULIZER. BY DELIVERING IN-002 DIRECTLY TO THE SITE OF INFECTION (THE AIRWAYS), WE EXPECT TO ACHIEVE HIGH DRUG CONCENTRATIONS WITH A LOWER DOSE OF MAB, SAVING COSTS AND POTENTIALLY IMPROVING EFFICACY. IN A NEONATAL LAMB MODEL OF RSV INFECTION, NEBULIZED THERAPY WITH IN-002 REDUCED RSV VIRAL LOAD IN THE LUNGS AND BALF TO ALMOST NON-DETECTIBLE LEVELS, UNLIKE PLACEBO-TREATED ANIMALS. INHALON IS THE FIRST COMPANY TO SUCCESSFULLY COMPLETE A PHASE 1 STUDY FOR AN INHALED MAB THERAPY (IN-006) FOR COVID, ACHIEVING VERY HIGH LEVELS OF DRUG IN THE AIRWAYS WITH AN EXCELLENT SAFETY PROFILE. INHALON HAS RECEIVED FDA FEEDBACK ON ITS PRE-IND SUBMISSION FOR IN-002, AND IS CURRENTLY COMPLETING IND-ENABLING PRECLINICAL ACTIVITIES FOR IN-002, INCLUDING GLP INHALATION TOX, GLP TISSUE CROSS REACTIVITY, AND GLP NEBULIZATION CHARACTERIZATION. FURTHER, INHALON HAS ALREADY ESTABLISHED A GMP-COMPLIANT MASTER CELL BANK FOR PRODUCTION OF IN-002, FROM WHICH SCALED UP PRODUCTION OF TOX MATERIALS HAVE ALREADY BEEN GENERATED. HERE, WE ARE SEEKING SUPPORT TO COMPLETE: (I) THE PRODUCTION, VIALING AND CHARACTERIZATION OF IN-002 CLINICAL TRIAL MATERIALS PRODUCED UNDER GMP (AIM 1), AND (II) IND SUBMISSION TO RECEIVE APPROVAL TO INITIATE PHASE 1 CLINICAL STUDIES (AIM 2). SUCCESSFUL COMPLETION OF THE PROPOSED ACTIVITIES WOULD ALLOW US TO ADVANCE IN-002 INTO FIRST-IN-HUMAN STUDIES.

HUMANITARIAN MINECLEARANCE IN ANTIOQUIA DEPARTMENT, COLOMBIA

HUMANITARIAN MINECLEARANCE IN SOMALILAND

NEW AWARD OBLIGATING $500,000 FOR HALO MOZAMBIQUE. SEE TERMS AND CONDITIONS AND SOO BELOW.

HUMANITARIAN MINECLEARANCE IN NORTHERN SRI LANKA

HUMANITARIAN MINE CLEARANCE IN COLOMBIA

PROVIDE SPECIALIZED COUNTER IMPROVISED EXPLOSIVE DEVICE (C-IED) AND EXPLOSIVE ORDNANCE DISPOSAL (EOD) TRAININGS TO THE CDI NATIONAL POLICE AND GENDARMERIE TO INCREASE THEIR CAPACITY TO EFFECTIVELY DISRUPT, DEGRADE, AND RESPOND TO TERRORIST ATTACKS.

HUMANTARIAN DEMINING

MINE CLEARANCE PROGRAM

INCREMENTALLY FUNDING AWARD AT $600.000. TOTAL AWARD AMOUNT IS $1M. SEE BELOW FOR TERMS AND CONDITIONS.

NEW AWARD OBLIGATING 1.683.076 TO SUPPORT HMA IN URIBE. POP 12 MONTHS. PRE-AWARD COSTS APPROVED FROM MARCH 1. SEE BELOW FOR TERMS AND CONDITIONS.

TAS::89 0222::TAS NEW PHASE I 2010 STTR; TITLE: HIGH TEMPERATURE UNIQUE LOW THERMAL CONDUCTIVITY THERMAL BARRIER COATING (TBC) ARCHITECTURES; PI:

COMMUNITY-CENTERED HEALTHY MARRIAGE AND RELATIONSHIP EDUCATION IN THE ORTHODOX JEWISH COMMUNITY OF NEW YORK CITY AND THE METROPOLITAN NYC AREA

NEW AWARD OBLIGATING $532,971 FOR AFRICA GREAT LAKES REGIONAL PROJECT. SEE TERMS AND CONDITIONS AND SOO BELOW.

HUMANITARIAN MINECLEARANCE IN MOZAMBIQUE

HMA

PHARMACOKINETICS ANALYSIS FROM FIRST-IN-HUMAN STUDY OF IN-002, A POTENT INHALED MUCO-TRAPPING ANTIBODY THERAPY FOR RSV - PROJECT SUMMARY RESPIRATORY SYNCYTIAL VIRUS (RSV) IS THE LEADING CAUSE OF VIRAL HOSPITALIZATION AND DEATH IN INFANTS AND YOUNG CHILDREN, AND ALSO A MAJOR CAUSE OF RESPIRATORY ILLNESS IN IMMUNOCOMPROMISED AND ELDERLY. UNFORTUNATELY, FOR THE MILLIONS INFECTED WITH RSV EACH YEAR, THERE IS NO CURRENTLY NO TREATMENT OPTION AVAILABLE. LIKE MANY RESPIRATORY PATHOGENS, RSV SPREADS IN THE LUNGS BY SHEDDING DAUGHTER VIRIONS FROM INFECTED CELLS EXCLUSIVELY BACK INTO THE AIRWAYS. FROM THERE, RSV MUST TRAVERSE THE AIRWAY MUCUS (AM) BEFORE INFECTING OTHER NEIGHBORING CELLS, REMAINING RESTRICTED TO THE AIRWAYS WITH LITTLE-TO-NO SYSTEMIC VIREMIA. THIS IMPORTANT MECHANISM OF SPREAD MAKES RSV DIFFICULT TO TARGET BY SYSTEMICALLY DOSED THERAPIES; THE ANTIVIRAL DRUGS NEED TO MAKE THEIR WAY TO THE AIRWAY MUCUS IN ORDER TO INACTIVATE VIRIONS AND HALT INFECTION. WE BELIEVE AN RSV-SPECIFIC, SAFE, AND EFFECTIVE ANTIVIRAL THERAPY THAT CAN BE INHALED DIRECTLY INTO THE RESPIRATORY TRACT USING A HAND-HELD DEVICE AT HOME WOULD PROVIDE A POWERFUL TREATMENT OPTION. TO MEET THIS GOAL, INHALON HAS BEEN ADVANCING IN-002, A MAB THAT BINDS AND NEUTRALIZES RSV F PROTEIN WITH PICOMOLAR AFFINITY, AND HAS MINIMAL RISKS OF VIRAL ESCAPE. IMPORTANTLY, IN ADDITION TO THE WELL-ESTABLISHED IGG FC EFFECTOR FUNCTIONS, IN-002 IS ALSO ENGINEERED TO POSSESS FC N-GLYCANS OPTIMIZED TO TRAP RSV IN AM. ONCE TRAPPED, RSV VIRIONS ARE QUICKLY PURGED FROM THE AIRWAYS VIA NATURAL MUCOCILIARY CLEARANCE MECHANISMS. WE HAVE FURTHER FORMULATED IN-002 TO BE STABLY NEBULIZED USING A PORTABLE VIBRATING MESH NEBULIZER. IN A NEONATAL LAMB MODEL OF RSV INFECTION, NEBULIZED IN-002 REDUCED RSV VIRAL LOAD IN THE LUNGS AND BALF TO ALMOST NON-DETECTIBLE LEVELS WITHIN JUST 3 DAYS. INHALON HAS ALREADY MANUFACTURED CLINICAL TRIAL MATERIALS, AND COMPLETED THE FULL RANGE OF IND-ENABLING STUDIES INCLUDING GLP INHALATION TOX, TISSUE CROSS-REACTIVITY AND NEBULIZATION CHARACTERIZATION STUDIES. INHALON IS THUS IN POSITION TO EXECUTE A PHASE 1 STUDY FOR IN-002 IN 2024. INHALON HAS STRONG EXPERIENCE CARRYING OUT CLINICAL STUDIES WITH ITS INHALED MAB PIPELINE, BEING THE FIRST COMPANY TO SUCCESSFULLY COMPLETE A PHASE 1 STUDY FOR AN INHALED MAB THERAPY FOR COVID (IN-006), AND MORE RECENTLY EXECUTED A PHASE 1B STUDY TO DIRECTLY COMPARE PULMONARY DISTRIBUTION OF THE SAME MAB GIVEN BY IV VS. BY INHALATION. THIS MAKES INHALON EXCEPTIONALLY WELL POSITIONED TO EXECUTE A PHASE 1 STUDY FOR IN-002. IN THIS PROPOSAL, WE SEEK TO OBTAIN SUPPORT TO COMPLETE THE NON-CLINICAL ACTIVITIES ASSOCIATED WITH THE PHASE 1 STUDY, INCLUDING PROCESSING OF COLLECTED CLINICAL TRIAL BIOSPECIMENS TO DETERMINE DRUG LEVELS IN NASAL SWABS AND SERUM, PERFORM BIOSTATISTICS CALCULATIONS AND PK MODELING, AND PERFORM THE MEDICAL WRITING TO COMPLETE THE CLINICAL STUDY REPORT. THESE ACTIVITIES WOULD IN TURN PUT INHALON IN A POSITION TO INITIATE A PHASE 2 STUDY TO DETERMINE THE EFFICACY OF IN-002 IN RSV-INFECTED INDIVIDUALS. THE WORK WILL FURTHER AID THE DEVELOPMENT OF FUTURE GENERATIONS OF INHALED, MAB-BASED THERAPIES FOR A VARIETY OF PULMONARY INDICATIONS.

IND-ENABLING DEVELOPMENT FOR IN-003, AN INHALED MAB THERAPY AGAINST HUMAN METAPNEUMOVIRUS INFECTION - PROJECT SUMMARY HUMAN METAPNEUMOVIRUS (MPV) IS THE SECOND LEADING CAUSE OF LOWER RESPIRATORY TRACT INFECTIONS (LRTI) IN INFANTS AND YOUNG CHILDREN, AND A MAJOR CAUSE OF RESPIRATORY ILLNESS AMONG THE IMMUNOCOMPROMISED AND THE ELDERLY. UNFORTUNATELY, THERE IS CURRENTLY NO EFFECTIVE THERAPY OR VACCINE FOR MPV. A PATHOGEN-SPECIFIC, SAFE AND EFFECTIVE ANTIVIRAL WOULD UNDOUBTEDLY ADDRESS THE CURRENT GAP IN PHARMACOLOGICAL INTERVENTIONS. MPV, LIKE MANY COMMON RESPIRATORY VIRUSES, SPREADS IN THE RESPIRATORY TRACT BY SHEDDING PROGENY (I.E. DAUGHTER) VIRIONS BACK INTO AIRWAY MUCUS (AM); VIRUSES MUST THEN DIFFUSE THROUGH AM TO REACH AND INFECT THE NEXT CELL. THUS, THE INFECTION REMAINS RESTRICTED TO THE APICAL SIDE OF THE AIRWAYS AS IT SPREADS FROM THE UPPER RESPIRATORY TRACT TO THE LOWER RESPIRATORY TRACT, MAKING IT DIFFICULT TO TARGET BY SYSTEMICALLY DOSED ANTIVIRALS. INDEED, WHILE NEUTRALIZING MONOCLONAL ANTIBODIES (MABS) OFFER A SAFE AND LIKELY EFFECTIVE ANTIVIRAL INTERVENTION, THEIR USE IS GREATLY LIMITED BY INCONVENIENT DOSING AND LIMITED DISTRIBUTION INTO THE RESPIRATORY TRACT. INHALON HAS BEEN ADVANCING A PLATFORM OF INHALED MAB TREATMENTS CAPABLE OF ACHIEVING VERY HIGH CONCENTRATIONS OF MAB DIRECTLY IN THE RESPIRATORY TRACT (I.E. THE SITE OF INFECTION) NEARLY INSTANTLY. SPECIFICALLY, WE HAVE DEVELOPED METHODS THAT ENABLE STABLE AND EFFICIENT DELIVERY OF MABS VIA HANDHELD VIBRATING MESH NEBULIZERS, WITH DOSING COMPLETED WITHIN MINUTES PER DAY IN THE COMFORT OF A PATIENT’S OWN HOME. INHALON HAS ALSO DEVELOPED A PLATFORM OF MUCO-TRAPPING MABS, BASED ON TUNING SUGARS ON THE FC DOMAIN OF MABS THAT ENABLE EFFECTIVE CROSSLINKING OF VIRION/MAB COMPLEXES TO MUCINS. MUCO-TRAPPING MABS CAN DIRECTLY BLOCK PROGENY VIRUSES FROM DIFFUSING THROUGH AM, AND CAN QUICKLY REMOVE THEM FROM THE AIRWAYS BY HARNESSING NATURAL MUCUS CLEARANCE MECHANISMS. WE HAVE VALIDATED OUR TOPICAL MAB THERAPY APPROACH IN HAMSTERS INFECTED WITH MPV, AS WELL AS IN LAMBS INFECTED WITH RSV (ANOTHER VIRUS THAT, LIKE MPV, PROPAGATES EXCLUSIVELY BY APICAL SHEDDING). RECENTLY, WE COMPLETED A PHASE 1 HUMAN CLINICAL STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF AN INHALED MAB AGAINST SARS-COV-2, AND FOUND EXCELLENT SAFETY AND HIGH CONCENTRATIONS OF DRUG IN THE AIRWAYS IN HUMANS, DESPITE USING A FAR LOWER DOSE COMPARED TO TYPICAL IV DOSES. INHALON IS ADVANCING IN-003, COMPRISED OF A PAIR OF POTENT NEUTRALIZING MABS AGAINST MPV F PROTEIN, AS AN INHALED MAB THERAPY AGAINST HMPV. BY DELIVERING IN-003 DIRECTLY TO THE AIRWAYS, WE EXPECT TO ENABLE EFFICACIOUS AND COST-EFFECTIVE TREATMENT FOR MPV, WITH LIMITED RISK OF ADVERSE SIDE EFFECTS. IN THIS PROJECT, WE SEEK TO PRODUCE A GLP TOX LOT BATCH OF IN-003, AND CONDUCT THE KEY GLP IND-ENABLING STUDIES REQUIRED BY THE FDA BEFORE ADVANCING TO THE CLINIC. THE PROPOSED WORK, BASED ON OUR RECENT REGULATORY EXPERIENCE ADVANCING INHALED MABS FOR SARS-COV-2 AND RSV, REPRESENTS THE CRITICAL PATH TO ADVANCE IN-003 INTO THE CLINIC. SUCCESSFUL COMPLETION OF THIS WORK WILL PUT US IN A POSITION TO QUICKLY FILE AN IND FOLLOWING GMP MANUFACTURING OF CLINICAL TRIAL MATERIALS, LEADING TO THE FIRST CLINICAL STUDY OF AN INHALED MAB THERAPY FOR MPV.

SBIR: IND-ENABLING DEVELOPMENT OF IN-007, AN INHALED MUCO-TRAPPING IMMUNOTHERAPY FOR COVID19 AND OTHER ACE2-TARGETED INFECTIONS - PROJECT SUMMARY DESPITE THE ROLLOUT OF VACCINES AND PAXLOVID FOR SARS-COV-2, THERE CONTINUES TO BE SIGNIFICANT DEMAND FOR TREATMENTS FOR COVID-19 THAT (I) CAN BE EASILY SELF-ADMINISTERED AT HOME, (II) REDUCE RISK OF HOSPITALIZATION, (III) RETAIN ACTIVITY AGAINST ALL VARIANTS OF CONCERN, AND (IV) FREE OF DRUG-DRUG INTERACTIONS. SARS-COV-2, LIKE MANY COMMON RESPIRATORY VIRUSES, SPREADS IN THE AIRWAYS BY SHEDDING PROGENY VIRIONS BACK UP INTO AIRWAY MUCUS (AM) BEFORE INFECTING THE NEXT CELL. THE INFECTION REMAINS ALMOST EXCLUSIVELY RESTRICTED TO THE APICAL SIDE OF THE AIRWAYS AS IT GRADUALLY SPREADS FROM THE UPPER RESPIRATORY TRACT TO THE LOWER RESPIRATORY TRACT. IMPORTANTLY, THIS MEANS THAT ANTIVIRAL TREATMENTS MUST REACH THE AIRWAYS TO HAVE MAXIMAL EFFECT. THE AM IS DIFFICULT TO REACH BY SYSTEMICALLY DOSED ANTIBODY-BASED THERAPIES, SINCE 1% OR LESS OF IV-INFUSED MABS DISTRIBUTE TO THE AM. UNFORTUNATELY, EVERY MONOCLONAL ANTIBODY (MAB) FOR COVID-19 TO DATE HAS BEEN DOSED SYSTEMICALLY. INHALON HAS PIONEERED METHODS FOR THE STABLE, EFFICIENT, INHALED DELIVERY OF ANTIBODY-BASED DRUGS FOR THE TREATMENT OF RESPIRATORY INFECTIONS USING HANDHELD NEBULIZERS THAT CAN ADMINISTER A DOSE WITHIN MINUTES PER DAY. INHALON HAS ALSO DEVELOPED A PLATFORM OF MUCO-TRAPPING MABS, BASED ON TUNING SUGARS ON THE FC DOMAIN OF MABS THAT ENABLE PHYSICAL TRAPPING OF VIRIONS TO MUCINS. MUCO-TRAPPING MABS ARE UNIQUE BECAUSE THEY CAN DIRECTLY REMOVE THE VIRUS FROM THE AIRWAYS BY HARNESSING NATURAL MUCUS CLEARANCE MECHANISMS. WE VALIDATED OUR INHALED MAB THERAPY APPROACH IN LAMBS INFECTED WITH RSV (A VIRUS THAT ALSO PROPAGATES EXCLUSIVELY BY APICAL SHEDDING); WHEN OUR NEBULIZED TREATMENT WAS GIVEN 3 DAYS POST-INFECTION (TIME OF PEAK VIRAL LOAD), THE TREATED ANIMALS BENEFITED FROM ROUGHLY 10,000-FOLD REDUCTIONS IN VIRAL LOAD, ALONG WITH EXCELLENT IMPROVEMENTS IN HISTOPATHOLOGY. RECENTLY, WE COMPLETED A PHASE 1 HUMAN CLINICAL STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ANOTHER INHALED MAB AGAINST SARS-COV-2, AND FOUND EXCELLENT SAFETY AND HIGH CONCENTRATIONS OF DRUG IN THE AIRWAYS, DESPITE USING A FAR LOWER DOSE THAN IV DOSING. HOWEVER, TRADITIONAL MABS ARE ALWAYS AT RISK OF VIRAL ESCAPE BY FUTURE VARIANTS, MOTIVATING US TO PURSUE A BROAD-SPECTRUM SOLUTION. INHALON IS ADVANCING IN-007, AN INHALED, PROPRIETARY, ACE2 DECOY-BASED MAB THAT RETAINS POTENT ACTIVITY AGAINST EVERY VARIANT OF SARS-COV-2 (INCLUDING OMICRON BA.4/5). IN-007 IS DESIGNED TO ACHIEVE BIVALENT BINDING, BOTH INTRA- AND INTER- S PROTEIN SPIKES. IN-007 IS INHERENTLY RESISTANT TO VIRAL ESCAPE, HAS MUCH GREATER BINDING AFFINITY THAN CONVENTIONAL ACE2-DECOYS, ENABLES POTENT TRAPPING OF SARS-COV-2 IN FRESH HUMAN AM, AND WAS EFFECTIVE IN TREATING SARS-COV-2 INFECTIONS IN A PILOT STUDY IN HAMSTERS. BY DELIVERING IN- 007 DIRECTLY TO THE AIRWAYS, WE EXPECT TO ENABLE EFFICACIOUS AND COST-EFFECTIVE TREATMENT FOR COVID-19, WITH LITTLE RISK OF ADVERSE SIDE EFFECTS. IN THIS PROJECT, WE SEEK TO PRODUCE A GLP BATCH OF IN-007, CONDUCT THE IND- ENABLING STUDIES THAT ARE REQUIRED BEFORE ADVANCING TO THE CLINIC, AND TEST EFFICACY IN VIVO (HAMSTERS) AND EX VIVO. THE PROPOSED WORK REPRESENTS THE CRITICAL PATH FOR RAPIDLY ADVANCING IN-007 FOR CLINICAL EVALUATION.

IND-ENABLING DEVELOPMENT FOR IN-002, AN INHALED MUCO-TRAPPING MAB AGAINST RESPIRATORY SYNCYTIAL VIRUS - PROJECT SUMMARY RESPIRATORY SYNCYTIAL VIRUS (RSV) IS THE LEADING CAUSE OF VIRAL DEATH IN INFANTS AND YOUNG CHILDREN, AND IS ALSO A MAJOR CAUSE OF RESPIRATORY ILLNESS IN IMMUNE COMPROMISED ADULTS AND THE ELDERLY. UNFORTUNATELY, THERE IS CURRENTLY NO VACCINE OR EFFECTIVE THERAPY AVAILABLE FOR RSV. SYNAGIS, A MONTHLY INTRAMUSCULAR INJECTION OF THE MONOCLONAL ANTIBODY (MAB) PALIVIZUMAB, IS THE ONLY FDA-APPROVED INTERVENTION, BUT CAN ONLY BE USED FOR PREVENTION AND IS GIVEN ONLY TO A VERY SMALL SUBSET OF HIGH-RISK INFANTS. SYNAGIS IS NOT EFFECTIVE AT TREATING RSV AFTER INFECTION HAS BEGUN. THUS, FOR THE TENS OF THOUSANDS HOSPITALIZED WITH RSV, ONLY SUPPORTIVE THERAPY IS AVAILABLE; THE RESULTING MORBIDITY AND MORTALITY ARE SUBSTANTIAL, PARTICULARLY AMONG THE IMMUNOCOMPROMISED. INTERESTINGLY, RSV SPREADS IN THE LUNG VIA SHEDDING OF VIRUS EXCLUSIVELY INTO THE AIRWAY; THUS, RSV MUST TRAVERSE THE AIRWAY MUCUS (AM) BEFORE INFECTING OTHER NEIGHBORING CELLS, AND REMAINS RESTRICTED TO THE AIRWAYS WITH LITTLE-TO-NO SYSTEMIC VIREMIA. THIS UNIQUE PATHOPHYSIOLOGY MAKES RSV DIFFICULT TO TARGET BY SYSTEMICALLY DOSED THERAPIES. WE BELIEVE AN RSV-SPECIFIC, SAFE AND EFFECTIVE ANTIVIRAL THERAPY THAT CAN BE INHALED DIRECTLY INTO THE RESPIRATORY TRACT WOULD PROVIDE A POWERFUL OPTION ADDRESSING THE CURRENT GAP IN PHARMACOLOGICAL INTERVENTIONS. TO MEET THIS GOAL, INHALON HAS BEEN ADVANCING IN-002, DEVELOPED USING ITS PROPRIETARY AND PATENTED “MUCO-TRAPPING” MAB TECHNOLOGY PLATFORM. IN-002 IS A POTENT ANTI-F MAB WITH PICOMOLAR BINDING AFFINITY AND NEUTRALIZATION POTENCY, HAS MINIMAL RISK OF VIRAL ESCAPE, AND POSSESS SUITABLE FC N-GLYCOSYLATION FOR TRAPPING RSV IN AM. IN TURN, TRAPPED RSV ARE QUICKLY PURGED FROM THE AIRWAYS VIA NATURAL MUCOCILIARY CLEARANCE MECHANISMS. WE HAVE FURTHER FORMULATED IN-002 TO BE STABLY NEBULIZED USING A VIBRATING MESH NEBULIZER. BY CONCENTRATING IN-002 DIRECTLY AT THE SITE OF INFECTION, RATHER THAN DELIVERING THE MAB SYSTEMICALLY, WE EXPECT TO ENABLE EFFICACIOUS AND COST-EFFECTIVE TREATMENT OF RSV, WITH LITTLE RISK OF ADVERSE SIDE EFFECTS DUE TO LIMITED SYSTEMIC ADSORPTION FROM PULMONARY DELIVERY. IN A NEONATAL LAMB MODEL OF RSV INFECTION, DAILY NEBULIZED THERAPY WITH IN-002 INITIATED EVEN AT NEAR PEAK VIRAL TITERS IN THE LUNG WAS ABLE TO REDUCE INFECTIOUS RSV VIRAL LOAD IN THE LUNGS AND BALF TO ALMOST NON-DETECTIBLE LEVELS WITHIN 3 DAYS. INHALON IS CURRENTLY ACTIVELY ENGAGING IN CELL LINE DEVELOPMENT FOR IN-002. TO ENABLE RAPID TRANSLATION INTO THE CLINIC, WE SEEK TO COMPLETE THE CELL LINE DEVELOPMENT IN THIS PROPOSAL, AND PRODUCE TOX MATERIALS SUITABLE FOR IND-ENABLING ACTIVITIES SUCH AS TISSUE CROSS REACTIVITY STUDIES, GLP PULMONARY TOX STUDIES, AND GLP NEBULIZATION CHARACTERIZATION STUDIES. TOGETHER, THE PROPOSED WORK WILL SUPPORT RAPID ADVANCEMENT OF IN-002 INTO CLINICAL TESTING. OUR WORK HERE WITH RSV WILL ALSO HELP PAVE THE WAY FOR IMPROVED, MOLECULARLY-TARGETED, INHALED THERAPIES FOR OTHER RESPIRATORY PATHOGENS.

NEW AWARD OBLIGATING $2,000,000 IN FY18 FMF OCO FUNDS FOR 51 MONTHS. TERMS AND CONDITIONS BELOW.

MINE ACTION AND WEAPONS AND AMMUNITION MANAGEMENT IN ANGOLA 2017

WEAPONS AND AMMUNITION MANAGEMENT IN ANGOLA AND WORKING TOWARDS A A?A*A?A?A?A?MINE IMPACT FREEA?A*A?A?A?A? HUAMBO

HUMANITARIAN MINE CLEARANCE

MINE CLEARANCE

HUMANITARIAN MINE CLEARANCE

MINE CLEARANCE OF LEGACY MINEFIELDS

YEMEN MINE ACTION CAPACITY BUILDING AND MENTORING

AWARDING $926.000 IN FY17/18 NADR-CWD ANGOLA BILAT FUNDS. POP 12 MONTHS. NO PRE-AWARD COSTS. INCREMENTAL FUNDING. SEE BELOW FOR TERMS AND CONDITIONS.

TAS::89 0321:TAS ROTATION-ENABLED 7-DOF SEISMOMETER FOR GEOTHERMAL RESOURCE DEVELOPMENT

HUMANITARIAN MINE CLEARANCE

SBIR PHASE II: AN ADJUVANT-BASED ANTIMICROBIAL COATING (COVID-19)

WEAPONS AND AMMUNITION DISPOSAL, MINE ACTION & PSSM IN SOMALIA

WEAPON AND AMMUNITION DISPOSAL

HUMANITARIAN MINE CLEARANCE

NEW COOPERATIVE AGREEMENT: DISTRIBUTED-BEAMFORMING FOR INTELLIGENT TRANSMISSION OF TACTICAL INFORMATION

NEW AWARD OBLIGATING $1,000,000.00 TO GUINEA-BISSAU. SEE TERMS AND CONDITIONS AND STATEMENT OF OBJECTIVES BELOW.

MINES AND ERW POSING A THREAT TO LIFE IN COLOMBIA

DEEP EUTECTIC SALT FORMATIONS SUITABLE AS ADVANCED HEAT TRANSFER FLUIDS

HEALTHY MARRIAGE DEMONSTRATION, PRIORITY AREA 8

WEAPONS REMOVAL & ABATEMENT GRANTS PROJECT: ISRAEL

PORTABLE MIXED REALITY-BASED PLATFORM FOR ASSESSMENT OF PROGRESS IN MULTISENSORY REHABILITATION STRATEGIES FOR POST-TBI RETURN-TO-DUTY (RTD) DECISION-MAKING

NEW AWARD OBLIGATING $2,000,000 IN FY19/20 NADR CWD ANGOLA BILAT FUNDS. TERMS AND CONDITIONS BELOW. PRE AWARD AUTHORIZED FROM MAY 1, 2020.

ASSISTED HOUSING STABILITY AND ENERGY AND GREEN RETROFIT INVESTMENTS PROGRAM (RECOVERY ACT FUNDED)

NEW AWARD OBLIGATING $1,440,000 (PREVIOUSLY SPMWRA15GR1004 - SAMS ERROR). THE TERMS AND CONDITIONS ARE BELOW.

NEW AWARD OBLIGATING $2,114,419 IN NADR-CWD FUNDS TO SUPPORT WAM IN SOMALIA. SEE TERMS AND CONDITIONS AND SOO BELOW.

ROAD CLEARANCE

GLOBAL SALW DIVERSION REPORTING

DEEP EUTECTIC SALT FORMULATIONS SUITABLE AS SUITABLE AS ADVANCED HEAT TRANSFER FLUIDS

HUMANITARIAN MINE CLEARANCE

WEAPONS AND AMMUNITION DISPOSAL

SAMPA: SECURITY ANALYSIS AND MONITORING TO PREVENT ABUSE OF HPC ENVIRONMENTS

ENABLING INTELLIGENT SECURITY ASSESSMENT FOR HPC SYSTEMS VIA AUTOMATED LEARNING AND DATA ANALYTICS

LEVERAGING A UNIVERSAL INNOVATION TAXONOMY: DRIVING NEW ENGAGEMENTS AND DIVERSE PARTNERSHIPS BETWEEN U.S. UNIVERSITIES AND INDUSTRY INNOVATORS -ACADEMIC-INDUSTRY PARTNERSHIPS FUEL INNOVATION IN HEALTH, SUSTAINABILITY, DEFENSE, AND OTHER AREAS. WHILE VARIOUS BESPOKE SERVICES CONNECT SUBSETS OF ACADEMIC RESEARCHERS WITH INDUSTRY, THERE IS NO CENTRALIZED PLATFORM FOR RESEARCHERS ACROSS A WIDE RANGE OF UNIVERSITIES AND COMPANIES TO EASILY IDENTIFY AREAS OF MUTUAL INTEREST AND CONNECT USING A SHARED TAXONOMY. THIS GAP RESULTS IN MISSED OPPORTUNITIES FOR BREAKTHROUGH INNOVATIONS THAT DEPEND ON THE UNIQUE AND VARIED BACKGROUNDS OF DIVERSE PARTICIPANTS. TO ADDRESS THIS GAP IN THE PARTNERING ECOSYSTEM, THIS PROJECT WILL EXPLORE HOW AN OPEN AND ACCESSIBLE DIGITAL PLATFORM THAT LEVERAGES A UNIVERSAL INNOVATION TAXONOMY CAN DRIVE NEW ENGAGEMENTS BETWEEN U.S. UNIVERSITIES AND INDUSTRY INNOVATORS. THE PROJECT TEAM WILL EXPLORE WHAT ENABLES OR BLOCKS SUCCESSFUL MATCHMAKING AND HOW A DIGITAL PLATFORM CAN DEMOCRATIZE ACCESS TO INDUSTRY PARTNERS REGARDLESS OF A RESEARCHER?S GEOGRAPHY OR INSTITUTIONAL STATUS. TO MAXIMIZE IMPACT, THIS PROJECT WILL INVOLVE THE DESIGN AND DEPLOYMENT OF SOFTWARE FEATURES ACCESSIBLE TO USERS (RATHER THAN PURE PROTOTYPES FOR LAB TESTING PURPOSES). AS A RESULT, THESE FEATURES WILL NOT ONLY SUPPORT THIS RESEARCH UNDERTAKING, BUT WILL ALSO FACILITATE NEW, DIVERSE, SUSTAINABLE AND IMPACTFUL REAL-WORLD PARTNERING RELATIONSHIPS. IN THIS PROJECT, THE RESEARCH EFFORTS WILL FOCUS ON DEVELOPING EFFECTIVE WAYS TO GROW NETWORKS OF RESEARCHERS AND INDUSTRY PARTNERS WITHIN THE SPECIFIC DOMAIN OF MATERIALS SCIENCE AND ENGINEERING. THE TEAM WILL INVESTIGATE THE PROJECT?S CENTRAL HYPOTHESIS THAT: EMPLOYING A UNIVERSAL TAXONOMY TO (A) CATEGORIZE UNIVERSITY AND COMPANY RESEARCHERS, (B) SUPPORT EFFECTIVE DISCOVERY AND MATCHMAKING, AND (C) FACILITATE A SELF-REINFORCING CYCLE OF NETWORK POPULATION GROWTH?WILL DRIVE NEW AND MORE DIVERSE PARTNERSHIPS ACROSS ALL INSTITUTIONS. THE FOCUS OF THIS EFFORT WILL BE TO TO DEMONSTRATE THAT THIS KIND OF AN APPROACH WILL BE VALUABLE ESPECIALLY TO INSTITUTIONS THAT ARE CLASSIFIED AS CARNEGIE R2. AFTER AN OPERATIONAL SETUP, THE PROJECT WILL FOLLOW THREE PHASES. THE TEAM WILL (1) DEVELOP TOOLS FOR CATEGORIZING AND MATCHMAKING RESEARCHERS, (2) DRIVE GROWTH OF THE RESEARCHER POPULATION USING MATERIALS SCIENCES AS THE INITIAL EXEMPLAR DOMAIN. THE PROCEDURE WILL CONSIST OF QUALITATIVE RESEARCH, PROTOTYPING, IMPLEMENTATION, AND DATA COLLECTION AND ANALYSIS. THE ANALYSIS AND SUGGESTIONS FOR FUTURE EXPLORATION WILL BE SHARED WITHIN THE SCIENTIFIC COMMUNITY THROUGH PUBLICATIONS, CONFERENCES, AND EVENTS (SUCH AS A JOINT WEBINAR SERIES WITH A RELEVANT TRADE ORGANIZATION) AND PROMOTED MORE BROADLY AS A MATTER OF PUBLIC INTEREST. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.- SUBAWARDS ARE NOT PLANNED FOR THIS AWARD.

MINECLEARANCE AND BATTLE AREA CLEARANCE IN GEORGIA

HUMANITARIAN MINE ACTION IN META, COLOMBIA

SARAH'S VOICE

LAV GRANT PROGRAM

SECURE AND LIGHTWEIGHT COMPUTING ENVIRONMENT FOR HPC SYSTEMS

SCALABLE FAULT DETECTION AND LOCALIZATION OF NETWORK ISSUES

JOINING OF CERAMIC COMPOSITES FOR NUCLEAR APPLICATIONS

YOUTH BUILD

BRITTLE FRACTURE WAFERING OF SILICON INGOTS FOR LOW COST, HIGH EFFICIENCY C-SI SOLAR CELLS

NEW AWARD OBLIGATING $1,463,000.00 IN FY18/19 NADR-CWD COLOMBIA BILATERAL FUNDS. POP OF 18 MONTHS. TERMS AND CONDITIONS BELOW.

SA/LW

HMA

SURVEY AND CLEARANCE IN KOSOVO

DEVELOPMENT OF IN-003PI AS PASSIVE IMMUNIZATION AGAINST HUMAN METAPNEUMOVIRUS INFECTION - PROJECT SUMMARY HUMAN METAPNEUMOVIRUS (MPV) IS THE SECOND LEADING CAUSE OF LOWER RESPIRATORY TRACT INFECTIONS (LRTI) IN INFANTS AND YOUNG CHILDREN, AND A MAJOR CAUSE OF RESPIRATORY ILLNESS IN THE IMMUNOCOMPROMISED AND THE ELDERLY. UNFORTUNATELY, THERE IS CURRENTLY NO EFFECTIVE THERAPY, PROPHYLAXIS, OR VACCINE AVAILABLE FOR MPV, AND ONLY SUPPORTIVE CARE IS AVAILABLE FOR THOSE HOSPITALIZED WITH MPV LRTIS. MPV LRTIS CAN BE LETHAL, WITH AN OBSERVED HOSPITAL MORTALITY RATE AMONG ALL MPV INFECTIONS OF ~10%, WHICH APPROXIMATES THE ~9% MORTALITY RATE FOR INFLUENZA-INFECTED ADULTS ADMITTED TO THE ICU. MPV SHARES MUCH OF THE SAME PATHOPHYSIOLOGY AS RSV, A CLOSELY RELATED RESPIRATORY INFECTION. RSV- INDUCED LRTIS IN INFANTS CAN BE EFFECTIVELY REDUCED BY PASSIVE IMMUNIZATION, AS ILLUSTRATED BY THE CLINICAL SUCCESS OF SYNAGIS® (PALIVIZUMAB), A MONTHLY SHOT GIVEN TO PREMATURE INFANTS DURING THE RSV SEASON FOR AT LEAST 20 YEARS, AND THE RECENTLY APPROVED BEYFORTUS® (NIRSEVIMAB), A ONE-TIME SHOT INDICATED FOR ALL INFANTS ENTERING THEIR FIRST RSV SEASON (NOT JUST HIGH-RISK INFANTS). THE CLINICAL EFFECTIVENESS OF BOTH SYNAGIS® AND BEYFORTUS®, WHICH REDUCE RSV LRTIS BY 70-80%, SUGGESTS THAT PASSIVE IMMUNIZATION SHOULD HELP SIMILARLY REDUCE RISK FOR MPV-LRTIS. INHALON IS A CLINICAL STAGE STARTUP FOCUSED ON ADVANCING INTERVENTIONS AGAINST DIVERSE RESPIRATORY INFECTIONS, INCLUDING MPV, RSV, SARS-COV-2, AND INFLUENZA. WE ARE ACTIVELY DEVELOPING IN-003 TO ADDRESS THE UNMET CLINICAL BURDEN OF MPV LRTIS. IN-003 IS COMPRISED OF A PAIR OF NEUTRALIZING MABS AGAINST MPV-F PROTEINS, ORIGINALLY IDENTIFIED FROM A LIBRARY OF HUMAN NEUTRALIZING MABS AGAINST MPV, EACH OF WHICH BIND AND NEUTRALIZE DIVERSE MPV STRAINS WITH PICOMOLAR AFFINITIES. IMPORTANTLY, BOTH MABS EXHIBIT STRONG RESISTANCE TO VIRAL ESCAPE. IN THIS WORK, WE PLAN TO ADVANCE IN-003PI (I.E. IN-003 FOR PASSIVE IMMUNIZATION) AGAINST MPV LRTIS. WE HAVE SHOWN IN VIVO THAT THE INDIVIDUAL IN-003 MABS OFFER EFFECTIVE PASSIVE IMMUNIZATION AGAINST MPV IN COTTON RATS AND MICE, AND ALSO PREVENT MPV INFECTIONS EX VIVO WHEN DOSED BASALLY TO WELL-DIFFERENTIATED HUMAN AIRWAY EPITHELIAL CULTURES PRIOR TO APICAL INOCULATION OF MPV. TO ENABLE ONCE-SEASONAL PROTECTION, THE IN-003 MABS WILL INCORPORATE LS MUTATIONS IN THE TO GREATLY INCREASE AFFINITY TO FCRN AND THEREFORE PROLONG CIRCULATION. HEREIN, WE WILL FILE A PRE-IND MEETING WITH THE FDA, PRODUCE A GLP TOX BATCH OF IN-003PI, AND CONDUCT KEY IND-ENABLING STUDIES, INCLUDING GLP TOX IN NON-HUMAN PRIMATES. THE PROPOSED WORK REPRESENTS THE CRITICAL PATH TO ADVANCE IN-003PI INTO THE CLINIC. SUCCESSFUL COMPLETION OF THIS WORK WILL PUT US IN A POSITION TO QUICKLY FILE IND FOLLOWING PRODUCTION OF GMP CLINICAL TRIAL MATERIALS FOR THE FIRST CLINICAL STUDY OF AN IMMUNOPROPHYLAXIS AGAINST MPV.

IND-ENABLING DEVELOPMENT FOR IN-005, AN INHALED MUCO-TRAPPING MAB THERAPY AGAINST INFLUENZA A - PROJECT SUMMARY SEASONAL INFLUENZA VIRUS (INFV) INFECTIONS REPRESENT A MAJOR PUBLIC HEALTH BURDEN. ALTHOUGH FLU VACCINES ARE BROADLY AVAILABLE, THEY ONLY OFFER MODEST EFFECTIVENESS AND HAVE LIMITED UPTAKE. CURRENT ANTIVIRALS ARE ONLY MODESTLY EFFECTIVE IF GIVEN SOON AFTER SYMPTOMS EMERGE (~24-48HRS), WHICH IS ACHIEVABLE IN LESS THAN HALF OF INFECTED PATIENTS DUE TO DELAYS IN SEEKING CARE AND CONFIRMING DIAGNOSIS. SEVERAL NEUTRALIZING MONOCLONAL ANTIBODIES (MAB) AGAINST INFV HAVE BEEN ADVANCED INTO PHASE 2 STUDIES OVER THE PAST 2 DECADES. HOWEVER, THEY HAVE ALL FAILED IN CLINICAL STUDIES DUE TO INABILITY TO CONSISTENTLY ACHIEVE THERAPEUTIC CONCENTRATIONS IN THE RESPIRATORY TRACT (RT) FOLLOWING IV DOSING. INDEED, IN CLINICAL STUDIES, THE SUBSET OF PATIENTS WHO EXPERIENCED THE GREATEST CLINICAL BENEFIT WERE THOSE WITH THE HIGHEST LEVELS OF MAB IN NASAL SWAB SAMPLES. THIS SUGGESTS THAT PRIOR CLINICAL FAILURES WERE PRIMARILY DUE TO INSUFFICIENT DISTRIBUTION OF MAB INTO RESPIRATORY FLUIDS AFTER IV ADMINISTRATION, NOT DUE TO DEFICIENCIES OF THE MABS THEMSELVES. INHALON IS ADVANCING A PIPELINE OF ANTIVIRAL MABS TO TREAT VARIOUS ACUTE RESPIRATORY INFECTIONS, TO BE DOSED DIRECTLY INTO THE RT VIA NEBULIZATION. DIRECT INHALED DELIVERY ALLOWS US TO ACHIEVE FAR HIGHER MAB CONCENTRATIONS IN THE RT THAN IV DOSING. INHALON ALSO INCORPORATES INTO ITS MAB PIPELINE A LARGELY UNDERAPPRECIATED MAB EFFECTOR FUNCTION IN MUCUS – TRAPPING INDIVIDUAL VIRUSES IN MUCUS – WHICH BLOCKS THE LOCAL SPREAD OF THE INFECTION AND FACILITATES RAPID ELIMINATION OF VIRIONS FROM THE RT, REMOVING A KEY SOURCE OF ANTIGENS THAT CAN PROPAGATE INFECTION-INDUCED INFLAMMATION. WE BELIEVE INHALON’S APPROACH TO COMBINE LOCALIZED DELIVERY WITH OPTIMIZED MUCOSAL EFFECTOR FUNCTION IS UNIQUELY WELL-SUITED TO TREAT VARIOUS ACUTE RESPIRATORY INFECTIONS, INCLUDING INFV. TO QUICKLY ADVANCE THIS CONCEPT INTO THE CLINIC, WE HAVE IN-LICENSED A BROADLY NEUTRALIZING MAB AGAINST INFV-A FROM LARGE PHARMA, WITH A WELL-ESTABLISHED CMC PACKAGE, EXISTING GMP MASTER CELL BANK, AND EXCELLENT SAFETY PROFILE ACROSS MULTIPLE CLINICAL STUDIES. WE HAVE TERMED THIS REFORMULATED MOLECULE IN-005, AND HAVE DEVELOPED FORMULATIONS THAT SUPPORT STABLE NEBULIZATION AT HIGH CONCENTRATIONS WHILE MAINTAINING PHYSICAL STABILITY AND FUNCTIONAL BINDING. IN AIM 1, WE WILL VERIFY WHETHER INHALED DOSING OF IN-005 CAN IMPROVE SURVIVAL AND REDUCE LUNG VIRAL TITERS RELATIVE TO OSELTAMIVIR STANDARD OF CARE, PARTICULARLY WHEN WITHHELD UNTIL AFTER OSELTAMIVIR’S EFFICACIOUS TREATMENT WINDOW. WE WILL, IN PARALLEL, SUBMIT A PRE-IND TO THE FDA (AIM 2A) TO CONFIRM THE NECESSARY PRECLINICAL AND CLINICAL PATHWAY, AND PRODUCE TOX MATERIALS USING AN EXISTING MASTER CELL BANK CHO CELL LINE (AIM 2B). THIS WILL ENABLE US TO COMPLETE THE KEY ADDITIONAL PRECLINICAL STUDIES (INHALATION TOX, NEBULIZATION CHARACTERIZATION, AIM 3) THAT, IN OUR EXPERIENCE WITH OTHER MABS IN OUR PIPELINE, WILL SUPPORT ADVANCING IN-005 INTO CLINICAL STUDIES. SUCCESSFUL COMPLETION OF THESE STUDIES WILL PUT IN-005 AT THE DOORSTEP OF CLINICAL STUDIES AS THE FIRST INHALED MAB THERAPY FOR INFV.

WAD

HMA IN CAMBODIA

BRITTLE FRACTURE WAFERING OF SILICON INGOTS FOR LOW COST, HIGH EFFICIENCY C‐SI SOLAR CELLS

THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE INCREMENTAL FUNDING IN THE AMOUNT OF $220,000.00 INCREASING THE TOTAL OBLIGATED AMOUNT FROM $1,700,000

EXPANDING SEXUAL ASSAULT SERVICES OUTREACH AND EDUCATION TO ORTHODOX JEWISH SURVIVORS IN THE NEW YORK METROPOLITAN AREA.

ADVANCED SILICON CARBIDE WAFER MANUFACTURING FOR LOW COST, HIGH EFFICIENCY POWER ELECTRONICS IN SOLAR APPLICATIONS

TO CULTIVATE BLACK-OWNED FARMING, FOOD SECURITY <(>&<)> ENHANCE HEALTHY NUTRITION OPTIONS, WHERE LONG STANDING SOCIAL, ECONOMIC <(>&<)> ENVIRONMENTAL DISPARITIES HAVE IMPACTED THE BLACK AND INDIGENOUS COMMUNITIES

**AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** RECHARGEABLE ANTIMICROBIAL COATING FOR POULTRY AND MEAT PROCESSING FACILITIES

DURABLE HIGH TEMPERATURE COATINGS FOR UTILITY SCALE GAS TURBINE HOT GAS PATH COMPONENTS

STABILIZATION THROUGH HUMANITARIAN MINECLEARANCE AND MANPADS SECURITY IN SOMALIA

UNDER THIS PROGRAM AFNSWAS AIMS TO EMPOWER KEY STAKHOLDERS IN SELECTED FIELDS TO CREATE INSTITUTIONAL CHANGE BY PROVIDING THEM WITH WITH TOOLS TO BEC

BUILDING HUMANITARIAN MINE ACTION CAPACITY

MINE CLEARANCE PROGRAM

HEALTH CENTER CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT FUNDING

CONVENTIONAL WEAPONS DESTRUCTION

HUMANITARIAN MINE CLEARANCE

IN SITU FUNCTIONALLY GRADED OXIDE MATRIX COMPOSITE FOR GAS TURBINE APPLICATIONS

MINE CLEARANCE

APPROVES A NEW AWARD FOR $427,608 TO HALO FOR GLOBAL SA/LW DIVERSION REPORTING. SEE AWARD PROVISIONS AND TERMS AND CONDITIONS BELOW. - GLOBAL

MINE CLEARANCE

MINE CLEARANCE PROGRAM

TAS::89 0321::TAS MULTIPHASE NANO-COMPOSITE COATINGS FOR ACHIEVING ENERGY OPTIMIZATION

THE HALO TRUST GEORGIA/ PM/WRA CLEARANCE OF RED BRIDGE & BARISAKHO MINEFIELDS

UWB ENHANCED TIME DIFFERENCE OF ARRIVAL SYSTEM

THE LEGAL ASSISTANCE FOR VICTIMS (LAV) GRANT PROGRAM, AUTHORIZED BY 34 U.S.C. 20121, IS INTENDED TO INCREASE THE AVAILABILITY OF CIVIL AND CRIMINAL LEGAL ASSISTANCE NEEDED TO EFFECTIVELY AID VICTIMS (AGES 11 AND OLDER) OF DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING BY PROVIDING FUNDS FOR COMPREHENSIVE DIRECT LEGAL SERVICES TO VICTIMS IN LEGAL MATTERS RELATING TO OR ARISING OUT OF THAT ABUSE OR VIOLENCE. LEGAL ASSISTANCE INCLUDES ASSISTANCE TO VICTIMS OF DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING IN: A) FAMILY, TRIBAL, TERRITORIAL, IMMIGRATION, EMPLOYMENT, ADMINISTRATIVE AGENCY, HOUSING MATTERS, CAMPUS ADMINISTRATIVE, OR PROTECTION OR STAY AWAY ORDER PROCEEDINGS, AND OTHER SIMILAR MATTERS; B) CRIMINAL JUSTICE INVESTIGATIONS, PROSECUTIONS, AND POST-TRIAL MATTERS (INCLUDING SENTENCING, PAROLE, AND PROBATION) THAT IMPACT THE VICTIMS SAFETY AND PRIVACY; C) ALTERNATIVE DISPUTE RESOLUTION, RESTORATIVE PRACTICES, OR OTHER PROCESSES INTENDED TO PROMOTE VICTIM SAFETY, PRIVACY, AND AUTONOMY; AND D) POST-CONVICTION RELIEF PROCEEDINGS IN STATE, LOCAL, TRIBAL, OR TERRITORIAL COURT WHERE THE CONVICTION OF A VICTIM IS RELATED TO OR ARISING FROM DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, STALKING, OR SEX TRAFFICKING. 34 U.S.C. 12291(A)(24)(C). THROUGH THIS CONTINUATION LEGAL ASSISTANCE FOR VICTIMS PROJECT, SHALOM TASK FORCE WILL PROVIDE CIVIL LEGAL ASSISTANCE TO VICTIMS OF DOMESTIC VIOLENCE, DATING VIOLENCE, STALKING, OR SEXUAL ASSAULT IN NEW YORK CITY, PRIMARILY KINGS, QUEENS, AND NEW YORK COUNTIES. THIS AWARD IS A CONTINUATION OF 15JOVW-22-GG-00300-LEGA.

HALO HOME TRANSITIONAL LIVING PROGRAM

EXPANDING PREVENTION AND INTERVENTION SERVICES TO ORTHODOX JEWISH YOUTH AND YOUNG ADULT VICTIMS OF DOMESTIC VIOLENCE SEXUAL ASSAULT AND TEEN DATING VIOLENCE IN NEW YORK CITY AND NASSAU COUNTY.

DISTRIBUTED BEAMFORMING

HUMANITARIAN MINE CLEARANCE

SOMALILAND DEMINING

HUMANITARIAN MINE CLEARANCE

HEALTH CENTER INFRASTRUCTURE SUPPORT

MINE CLEARANCE

WEAPONS DESTRUCTION, EOD AND PSSM IN GUATEMALA

WEAPONS AND AMMUNITION DESTRUCTION, STOCKPILE MANAGEMENT TRAINING AND PSSM UPGRADES

UNEXPLODED ORDNANCE DISPOSAL, AMMUNITION DISPOSAL, WEAPONS CUTTING AND OPERATION OF THE ABKHAZIA MINE ACTION OFFICE (AMAO)

HALO TRANSITIONAL LIVING/MATERNITY GROUP HOME INITIATIVE

WEAPONS AND MUNITIONS DESTRUCTION, STOCKPILE MANAGEMENT TRAINING AND PSSM UPGRADES IN HONDURAS

MINECLEARANCE, EOD AND SURVEY

PURPOSE: THE CONTINUUM OF CARE (COC) PROGRAM IS DESIGNED TO PROMOTE COMMUNITY-WIDE COMMITMENT TO THE GOAL OF ENDING HOMELESSNESS; PROVIDE FUNDING FOR EFFORTS BY NONPROFIT PROVIDERS, STATES, AND LOCAL GOVERNMENTS TO QUICKLY HOUSE HOMELESS INDIVIDUALS AND FAMILIES WHILE MINIMIZING THE TRAUMA AND DISLOCATION CAUSED TO HOMELESS INDIVIDUALS, FAMILIES, AND COMMUNITIES BY HOMELESSNESS; PROMOTE ACCESS TO AND EFFECTIVE UTILIZATION OF MAINSTREAM PROGRAMS BY HOMELESS INDIVIDUALS AND FAMILIES; AND OPTIMIZE SELF-SUFFICIENCY AMONG INDIVIDUALS AND FAMILIES EXPERIENCING HOMELESSNESS. THE MOST RECENT COC AWARD ANNOUNCEMENT LISTING AWARDS BY STATE AND COC IS ACCESSIBLE AT HTTPS://WWW.HUD.GOV/PROGRAM_OFFICES/COMM_PLANNING/COC/AWARDS. SELECT THE LINK UNDER THE FUNDING AND AWARD INFORMATION SECTION FOR THE APPROPRIATE FISCAL YEAR.; ACTIVITIES TO BE PERFORMED: CONTINUUM OF CARE PROGRAM FUNDS MAY BE USED TO PAY FOR THE ELIGIBLE COSTS USED TO ESTABLISH AND OPERATE PROJECTS UNDER FIVE PROGRAM COMPONENTS: (1) PERMANENT HOUSING, WHICH INCLUDES PERMANENT SUPPORTIVE HOUSING FOR PERSONS WITH DISABILITIES, AND RAPID REHOUSING; (2) TRANSITIONAL HOUSING; (3) SUPPORTIVE SERVICES ONLY; (4) HOMELESS MANAGEMENT INFORMATION SYSTEMS (HMIS), AND (5) IN SOME CASES, HOMELESSNESS PREVENTION. THIRTEEN TYPES OF ASSISTANCE MAY BE PROVIDED THROUGH THE CONTINUUM OF CARE (COC) PROGRAM: (1) COC PLANNING ACTIVITIES/COSTS FOR DESIGNING AND CARRYING OUT A COLLABORATIVE PROCESS FOR THE DEVELOPMENT OF AN APPLICATION TO HUD; (2) UNITED FUNDING AGENCY (UFA) COSTS FOR FISCAL CONTROL AND ACCOUNTING NECESSARY TO ASSURE THE PROPER DISBURSAL OF, AND ACCOUNTING FOR, FEDERAL FUNDS AWARDED TO SUBRECIPIENTS UNDER THE CONTINUUM OF CARE PROGRAM, (3) ACQUISITION OF REAL PROPERTY (INCLUDING STRUCTURES) FOR USE IN THE PROVISION OF HOUSING OR SUPPORTIVE SERVICES; (4) REHABILITATION OF STRUCTURES TO PROVIDE HOUSING OR SUPPORTIVE SERVICES; (5) NEW CONSTRUCTION, INCLUDING THE BUILDING OF A NEW STRUCTURE OR BUILDING AN ADDITION TO AN EXISTING STRUCTURE FOR USE AS SUPPORTIVE HOUSING; (6) LEASING OF A STRUCTURE OR STRUCTURES, OR PORTIONS THEREOF, TO PROVIDE HOUSING OR SUPPORTIVE SERVICES; (7) RENTAL ASSISTANCE, WHICH MAY BE SHORT-TERM, MEDIUM-TERM, OR LONG-TERM, AS WELL AS TENANT-BASED, PROJECT-BASED, OR SPONSOR-BASED, FOR TRANSITIONAL OR PERMANENT HOUSING; (8) SUPPORTIVE SERVICES TO ASSIST PROGRAM PARTICIPANTS OBTAIN AND MAINTAIN HOUSING; (9) OPERATING COSTS OF SUPPORTIVE HOUSING; (10) COSTS OF IMPLEMENTING AND OPERATING HMIS; (11) PROJECT ADMINISTRATIVE COSTS; (12) RELOCATION COSTS; AND (13) INDIRECT COSTS IN ACCORDANCE WITH 2 CFR PARTS 200, AS APPLICABLE. IN ADDITION TO USING GRANT FUNDS FOR THE ELIGIBLE COSTS DESCRIBED ABOVE, RECIPIENTS AND SUBRECIPIENTS IN CONTINUUMS OF CARE DESIGNATED AS HIGH PERFORMING COMMUNITIES MAY ALSO USE GRANT FUNDS TO PROVIDE HOUSING RELOCATION AND STABILIZATION SERVICES AND SHORT- AND/OR MEDIUM-TERM RENTAL ASSISTANCE TO INDIVIDUALS AND FAMILIES AT RISK OF HOMELESSNESS AS SET FORTH IN 24 CFR 576.103 AND 24 CFR 576.104, IF NECESSARY TO PREVENT THE INDIVIDUAL OR FAMILY FROM BECOMING HOMELESS. LIMITATION ON USE OF FUNDS: NO ASSISTANCE PROVIDED UNDER PROGRAM (OR ANY STATE OR LOCAL GOVERNMENT FUNDS USED TO SUPPLEMENT THIS ASSISTANCE) MAY BE USED TO REPLACE STATE OR LOCAL FUNDS PREVIOUSLY USED, OR DESIGNATED FOR USE, TO ASSIST HOMELESS PERSONS OR PERSONS AT-RISK OF HOMELESSNESS.; EXPECTED OUTCOMES: DECREASE IN THE NUMBER INDIVIDUALS AND FAMILIES EXPERIENCING HOMELESSNESS, MORE SPECIFICALLY USING PERFORMANCE INDICATORS SUCH AS THE LENGTH OF TIME HOMELESS, RETURNS TO HOMELESSNESS OVER TIME, AND EXITS TO PERMANENT HOUSING. COC PERFORMANCE PROFILE REPORTS CAN BE FOUND AT HTTPS://WWW.HUDEXCHANGE.INFO/PROGRAMS/COC/COC-PERFORMANCE-PROFILE-REPORTS/.; INTENDED BENEFICIARIES: INDIVIDUALS AND FAMILIES EXPERIENCING HOMELESSNESS.; SUBRECIPIENT ACTIVITIES: THE SUBRECIPIENT ACTIVITIES ARE UNKNOWN AT THE TIME OF AWARD.

NEW AWARD OBLIGATING $606,930. SEE TERMS AND CONDITIONS AND SOO BELOW. - WEST BANK

TECHNICAL SURVEY, CLEARANCE AND CAPACITY BUILDING IN ARMENIA

FORTY-EIGHT MILLION PEOPLE SUFFER FROM FOODBORNE ILLNESSES EVERY YEAR AND 3,000 PEOPLE DIE. WHILE THE HUMAN COST IS IMMENSE AND TRAGIC, THE COST TO FOOD COMPANIES CAN BE EQUALLY STEEP. THE AVERAGE COST OF A RECALL FOR FOOD PROCESSORS CAN BE AS MUCH AS $10 MILLION IN DIRECT COSTS, AND, EVEN WORSE, RESULT IN 50% DROP IN SALES FOR THE FIRST YEAR. SOME FOOD PROCESSING COMPANIES HAVE BEEN COMPLETELY WIPED OUT. THE CURRENT SANITATION PROTOCOLS, NAMELY DAILY APPLICATIONS OF SHORT-LIVED DISINFECTANTS, ARE CLEARLY INSUFFICIENT FOR TODAY&#39;S COMPLEX FOOD PROCESSING ENVIRONMENT. SELF-SANITIZING COATINGS, I.E. ANTIMICROBIAL SURFACES, ARE AN IDEAL THEORETICAL SOLUTION FOR ELIMINATING PERSISTENT PATHOGENS; HOWEVER THERE HAS BEEN NO COMMERCIALLY AVAILABLE ANTIMICROBIAL MATERIAL WHICH CAN FULFILL ALL REQUIREMENTS OF HIGH-EFFICACY AGAINST PATHOGENS: EASY TO APPLY, BROAD MATERIAL COMPATIBILITY, NO PATHOGEN RESISTANCE DEVELOPMENT, AND COST-EFFECTIVE.THAT MAKES HALOFILM&TRADE; A BREAKTHROUGH PRODUCT. HALOFILM IS A SPRAY-ON PRODUCT THAT WHEN DRIED LEAVES A THIN TRANSPARENT FILM ON A SURFACE. THE FILM IS A POLYMER COMPOSED OF ONE MONOMER TO STICK TO THE SURFACE, AND ANOTHER MONOMER THAT STABILIZES CHLORINE, I.E. N-HALAMINE. HALOFILM TURNS THE SURFACE INTO A CHLORINE BATTERY SO USING A CHLORINATED CLEANING PRODUCT WILL LEAVE A SURFACE COVERED WITH CHLORINE WHICH CAN LAST DAYS. HALOFILM, ESSENTIALLY A CHLORINE EXTENDER, RELIES ON THE EFFICACY OF CHLORINE WHICH HAS DECADES OF USE, AND BROAD-SPECTRUM EFFICACY AGAINST PATHOGEN WITHOUT GENERATING PATHOGENS WITH RESISTANCE.THE VALUE PROPOSITION FOR HALOFILM IN THIS CONTEXT IS CLEAR. THERE ARE TWO MAJOR SCENARIOS WHERE HALOFILM CAN BE OF BENEFIT: (1) ERRANT PATHOGENS AND INCOMPLETE CLEANING PROCEDURES THAT DON&#39;T KILL ALL PATHOGENS HAVE A LOWER LIKELIHOOD OF RESULTING IN TAINTED FOOD PRODUCTS, AND (2) BIOFILMS, WHICH ARE THE BANE OF FOOD PROCESSING PLANTS, HAVE LESS OF A CHANCE TO TALK HOLD FROM THE START. AT THE SAME TIME, A FORMULATION WITH ZWITTERION MOIETIES IN THE POLYMER BACKBONE MAY ENHANCE THE CLEANING EFFORT BY REDUCING THE LIKELIHOOD OF ORGANIC MATTER TO STICK TO SURFACES.BUILDING ON THE SUCCESSFUL RESULTS FROM OUR PHASE I EFFORT, WE WILL PURSUE THREE OBJECTIVES WITH THIS PHASE II. FIRST, WE WILL PERFORM ADDITIONAL PRODUCT DEVELOPMENT TO SUFFICIENTLY CHARACTERIZE THE BASE FORMULATION OF HALOFILM, AND A FORMULATION THAT INCLUDES ADDITIONAL ELEMENTS IN THE POLYMERIC BACKBONE THAT MIGHT CONTRIBUTE TO A REDUCED NEED FOR CLEANING. SECONDLY, WE WILL PERFORM PRODUCT PERFORMANCE STUDIES TO VALIDATE THE ANTI-PROTEIN AND ANTI-MICROBIAL FUNCTION OF HALOFILM ON REAL FOOD MACHINE WITH CONTROLLED INOCULATION REGIMES. THIRDLY, WE WILL ASSESS THE MANUFACTURING EFFORTS AND PERFORM LIMITED SCALE-UP EFFORTS TO VALIDATE OUR MANUFACTURING APPROACH. THE RESULTS OF THESE EFFORTS SHOULD DEMONSTRATED HALOFILM&#39;S FEATURES, PERFORMANCE AND UTILITY.HALOFILM IS HALOMINE INC.&#39;S FIRST PRODUCT AND IS PROTECTED BY EXCLUSIVELY LICENSEDPATENTS FROM AUBURN UNIVERSITY AND CORNELL UNIVERSITY. OUR BUSINESS MODEL IS TO MAKE AND SELL HALOFILM WITH REVENUE COMING FROM SALES OF PRODUCT. WE BELIEVE THE MARKET FOR DISINFECTANTS RELATED TO FOOD SAFETY IS LIKELY BETWEEN $600 AND $800 MILLION WITH SEVERAL TIMES THAT SPENT ON THE ACTIVITY, AND BELIEVE WE HAVE A TOTAL AVAILABLE MARKET OF OVER $100 MILLION. THERE ARE SIX INITIAL TARGET APPLICATIONS THAT ENCOMPASS ABOUT 3,000 OUT OF THE 27,000 FOOD MANUFACTURING FIRMS: FROZEN FOOD, FROZEN DESSERTS, SEAFOOD, PET FOOD, CHEESE, AND BREAKFAST CEREAL.

THE TRAINING AND SERVICES TO END VIOLENCE AND ABUSE AGAINST INDIVIDUALS WITH DISABILITIES AND DEAF PEOPLE GRANT PROGRAM (DISABILITY PROGRAM) IS AUTHORIZED BY 34 U.S.C. 20122. THE GOAL OF THE DISABILITY PROGRAM IS TO CREATE SUSTAINABLE CHANGE WITHIN AND BETWEEN ORGANIZATIONS THAT IMPROVES THE RESPONSE TO INDIVIDUALS WITH DISABILITIES AND DEAF INDIVIDUALS WHO ARE VICTIMS OF DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, STALKING, AND CAREGIVER ABUSE, AND TO HOLD PERPETRATORS OF SUCH CRIMES ACCOUNTABLE. THE DISABILITY GRANT PROGRAM BRINGS TOGETHER DISABILITY ORGANIZATIONS AND VICTIM SERVICE PROVIDERS TO WORK IN A COLLABORATIVE MANNER AT THE INTERSECTION OF DISABILITY AND DOMESTIC AND SEXUAL VIOLENCE. SHALOM TASK FORCE, INC WILL COLLABORATE WITH OHEL CHILDRENS HOME AND FAMILY SERVICES TO STRENGTHEN PARTNERSHIPS AND ESTABLISH A MULTIDISCIPLINARY COLLABORATIVE TEAM (TEAM); INCREASE ORGANIZATIONAL CAPACITY TO PROVIDE ACCESSIBLE, SAFE, AND EFFECTIVE SERVICES TO INDIVIDUALS WITH DISABILITIES AND DEAF INDIVIDUALS WHO ARE VICTIMS OF VIOLENCE AND ABUSE; IDENTIFY NEEDS WITHIN THE GRANTEES ORGANIZATION AND/OR SERVICE AREA; AND DEVELOP A PLAN THAT ADDRESSES THOSE IDENTIFIED NEEDS AND BUILDS A STRONG FOUNDATION FOR FUTURE WORK. THE AWARD IS SEPARATED INTO TWO PHASES: 1) THE PLANNING AND DEVELOPMENT PHASE AND 2) THE IMPLEMENTATION PHASE. DURING THE PLANNING AND DEVELOPMENT PHASE, EACH TEAM WILL ENTER INTO A COLLABORATIVE RELATIONSHIP, ENGAGE IN CAPACITY BUILDING ACTIVITIES, DEVELOP A COLLABORATION CHARTER, CONDUCT A NEEDS ASSESSMENT, AND DEVELOP A STRATEGIC PLAN AND PROJECT FOCUS MEMO. THE IMPLEMENTATION PHASE WILL COMMENCE AFTER COMPLETION OF THE PLANNING AND DEVELOPMENT PHASE AND OVW APPROVAL OF THE STRATEGIC PLAN. DURING THE IMPLEMENTATION PHASE, EACH TEAM WILL IMPLEMENT THE INITIATIVES IDENTIFIED DURING THE PLANNING AND DEVELOPMENT PERIOD. THROUGHOUT THE PROJECT, EACH TEAM WILL RECEIVE INTENSIVE TECHNICAL ASSISTANCE AND SUPPORT THROUGH A COMBINATION OF MEETINGS, ON-SITE CONSULTATIONS, WEB RESOURCES, AND TELE/VIDEO CONFERENCE CALLS. EACH MEMBER OF THE TEAM WILL BE EXPECTED TO ADDRESS ISSUES OF ACCESSIBILITY AND SAFETY WITHIN THEIR OWN ORGANIZATIONAL SERVICE AND EMPLOYMENT PRACTICES. EACH ORGANIZATION IS EXPECTED TO DEVELOP AND IMPLEMENT POLICIES THAT ADDRESS ACCESS AND SAFETY AND A REALISTIC PLAN TO SUSTAIN PROJECT ACTIVITIES.

THE GRANTS FOR OUTREACH AND SERVICES TO UNDERSERVED POPULATIONS (UNDERSERVED PROGRAM) WAS STATUTORILY CREATED IN THE VIOLENCE AGAINST WOMEN REAUTHORIZATION ACT OF 2013 TO DEVELOP AND IMPLEMENT OUTREACH STRATEGIES TARGETED AT ADULT OR YOUTH VICTIMS OF DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, OR STALKING IN UNDERSERVED POPULATIONS, AND TO PROVIDE VICTIM SERVICES TO MEET THE NEEDS OF SUCH POPULATIONS. GRANT FUNDS MAY BE USED TO: 1) WORK WITH FEDERAL, STATE, TRIBAL, TERRITORIAL, AND LOCAL GOVERNMENTS, AGENCIES, AND ORGANIZATIONS TO DEVELOP OR ENHANCE POPULATION SPECIFIC VICTIM SERVICES; 2) STRENGTHEN THE CAPACITY OF UNDERSERVED POPULATIONS TO PROVIDE POPULATION SPECIFIC VICTIM SERVICES; 3) STRENGTHEN THE CAPACITY OF TRADITIONAL VICTIM SERVICE PROVIDERS TO PROVIDE POPULATION SPECIFIC VICTIM SERVICES; 4) STRENGTHEN THE EFFECTIVENESS OF CRIMINAL AND CIVIL JUSTICE INTERVENTIONS BY PROVIDING TRAINING FOR LAW ENFORCEMENT, PROSECUTORS, JUDGES, AND OTHER COURT PERSONNEL ON DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, OR STALKING IN UNDERSERVED POPULATIONS; 5) WORK IN COOPERATION WITH AN UNDERSERVED POPULATION TO DEVELOP AND IMPLEMENT OUTREACH, EDUCATION, PREVENTION, AND INTERVENTION STRATEGIES THAT HIGHLIGHT AVAILABLE RESOURCES AND THE SPECIFIC ISSUES FACED BY VICTIMS OF DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, OR STALKING FROM UNDERSERVED POPULATIONS; OR (6) PROVIDE POPULATION-SPECIFIC TRAINING FOR SOCIAL AND HUMAN SERVICES PROVIDERS ON DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, OR STALKING IN UNDERSERVED POPULATIONS. SHALOM TASK FORCE (STF) WILL PARTNER WITH THE BETH ISRAEL MEDICAL CENTERS SUPPORT FOR ORTHODOX VICTIMS OF RAPE AND INCEST (SOVRI) HELPLINE TO ADDRESS DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING IN THE ORTHODOX JEWISH COMMUNITY IN NEW YORK CITY. THROUGH THIS CONTINUATION AWARD, THE PROJECT WILL: 1) MAINTAIN THE STF HOTLINE AND THE SOVRI HELPLINE TO PROVIDE CRISIS INTERVENTION, SUPPORTIVE LISTENING, AND REFERRALS; 2) DEVELOP TELEPHONE CASE MANAGEMENT FOLLOW UP SERVICES FOR VICTIMS; 3) PROVIDE INDIVIDUAL OR GROUP COUNSELING, THERAPY, AND PSYCHO-EDUCATION TO SURVIVORS; 4) PROVIDE OUTREACH, EDUCATION AND TRAINING ON DOMESTIC VIOLENCE, SEXUAL ASSAULT, STALKING AND TECHNOLOGY TO ORTHODOX JEWISH RABBIS, RELIGIOUS LEADERS, MENTAL HEALTH PROFESSIONALS, SOCIAL WORKERS, EDUCATORS AND OTHER PROFESSIONALS; 5) CONDUCT COMMUNITY AND PREVENTION EDUCATION PROGRAMS TO ORTHODOX JEWISH YOUTH AND ADULTS.

THE LEGAL ASSISTANCE FOR VICTIMS (LAV) GRANT (LAV) PROGRAM, AUTHORIZED BY 34 U.S.C. § 20121, INCREASES THE AVAILABILITY OF CIVIL AND CRIMINAL LEGAL ASSISTANCE FOR ADULT AND YOUTH VICTIMS OF DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING BY PROVIDING FUNDS FOR COMPREHENSIVE DIRECT LEGAL SERVICES TO VICTIMS IN LEGAL MATTERS RELATING TO OR ARISING OUT OF THAT ABUSE OR VIOLENCE. “LEGAL ASSISTANCE” INCLUDES ASSISTANCE IN: A) FAMILY, TRIBAL, TERRITORIAL, IMMIGRATION, EMPLOYMENT, ADMINISTRATIVE AGENCY, HOUSING MATTERS, CAMPUS ADMINISTRATIVE, OR PROTECTION OR STAY AWAY ORDER PROCEEDINGS, AND OTHER SIMILAR MATTERS; AND B) CRIMINAL JUSTICE INVESTIGATIONS, PROSECUTIONS, AND POST-TRIAL MATTERS (E.G., SENTENCING, PAROLE, AND PROBATION) THAT IMPACT THE VICTIM’S SAFETY AND PRIVACY. LAV FUNDS PROJECTS THAT IMPLEMENT, EXPAND, AND/OR ESTABLISH THIS COMPREHENSIVE LEGAL ASSISTANCE THROUGH (1) COLLABORATIONS BETWEEN LEGAL ASSISTANCE PROVIDERS AND DOMESTIC VIOLENCE, DATING VIOLENCE, AND SEXUAL ASSAULT VICTIM SERVICE PROVIDERS; (2) EFFORTS BY ORGANIZATIONS WITH A DEMONSTRATED HISTORY OF PROVIDING DIRECT LEGAL OR ADVOCACY SERVICES ON BEHALF OF VICTIMS OF DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND STALKING; OR (3) COMPETENT SUPERVISED PRO BONO LEGAL ASSISTANCE. GRANTEES MUST EITHER DEMONSTRATE EXPERTISE ON DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, AND/OR STALKING, OR PARTNER WITH AN ORGANIZATION THAT HAS SUCH EXPERTISE. THE TIMING FOR PERFORMANCE OF THIS AWARD IS 36 MONTHS.

SBIR PHASE II: ADVANCED MOLTEN SALT FOR SOLAR THERMAL POWER GENERATION WITH SUPERCRITICAL STEAM TURBINES

NEW WITH NO OPTION YEARS. AWARDING $581.988 IN FY17/18 SRI LANKA BILATERAL FUNDS. TERMS AND CONDITIONS ATTACHED.

CONTINUUM OF CARE PROGRAM

REHABILITATION OF MINOR ROADS IN ABKHAZIA PROJECT

WEAPONS REMOVAL & ABATEMENT GRANTS PROJECT: ANGOLA

REAP RENEWABLE ENERGY SYSTEM (RES) GRANT UNRESTRICTED AMOUNT

STTR PHASE II: A NEW PROCESS FOR BORIDE COATINGS FOR MANUFACTURING APPLICATIONS

NEW AWARD FOR $500,000 WITH 4 OPTION YEARS TO CLEAR UXO IN THE VICINITY OF PRIMORSKY, GEORGIA. PLEASE FIND TERMS AND CONDITIONS AND SOO BELOW.

THE HALO TRUST ZIMBABWE MINECLEARANCE PROGRAMPROGRAM

THIS PROJECT LEAD BY HALO HANDS FOUNDATION, INC WILL PROVIDE USDA NRCS- MICHIGAN WITH PROFESSIONAL SERVICES TO PROVIDE LEADERSHIP AND OVERSIGHT FOR ITS OUTREACH PROGRAM TO ENGAGE DIVERSE COMMUNITIES, INCREASE AWARENESS OF NRCS PROGRAMS.

** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** IN COLLABORATION WITH MULTIPLE HEALTHCARE PARTNERS, SHALOM FARMS WILL IMPLEMENT A 6 MONTHPRODUCE PRESCRIPTION PROGRAM FOR 3 COHORTS OF 20 PARTICIPANTS EACH YEAR FOR THREE YEARS.PARTICIPANT HEALTH OUTCOMES WILL BE COLLECTED BY CLINICAL PARTNERS AT THE BEGINNING OF THE PROGRAMAND AGAIN AT THE CONCLUSION OF EACH PHASE. EACH COHORT WILL INCLUDE A 12 WEEK ACTIVEMANAGEMENT PHASE AND A 12 WEEK SUSTAINABILITY PHASE. THIS PROJECT SEEKS TO UNDERSTAND WHETHERTHE FOLLOWING INTERVENTIONS INDUCE MEASURABLE, MEANINGFUL HEALTH BEHAVIOR CHANGES: 12 WEEKS OFACTIVE PROGRAMMING COMBINED WITH 12 WEEKS OF SUSTAINED MANAGEMENT, COACHING AND PEERSUPPORT, AND NUTRITION AND FOOD SKILLS EDUCATION.THE PROJECT&#39;S GOALS ARE AS FOLLOWS: TO INCREASE ACCESS TO FRESH, LOCAL, GUSNIP-QUALIFYING FRUITS AND VEGETABLES FOR INDIVIDUALS EXPERIENCING FOOD INSECURITY AND/OR MANAGING CHRONIC DIET RELATED CONDITIONS. TO EXPAND KNOWLEDGE OF COOKING SKILLS IN ORDER TO INCREASE UTILIZATION OF FRESH PRODUCE WITHIN PARTICIPANT DIETS. AND TO DECREASE UTILIZATION OF HEALTHCARE SERVICES FOR CHRONIC, DIET-RELATED DISEASE THROUGH INCREASED CONSUMPTION OF FRESH PRODUCESHALOM FARMS IS UNIQUELY POSITIONED TO ADMINISTER THIS PILOT PROJECT DUE TO THEIR DECADELONG HISTORY OF OPERATING THE PROGRAM IN COLLABORATION WITH MULTIPLE PARTNERS. THE ORGANIZATIONHAS A LONG-STANDING COMMITMENT TO THE COMMUNITIES IT SERVES, AND HAS A PROVEN AND TRUSTEDREPUTATION OF DELIVERING HIGH QUALITY PROGRAMMING TO THOSE MOST IN NEED. FURTHER, THEORGANIZATION IS UNIQUELY POSITIONED FOR PRODUCE-CENTERED PROGRAMMING BECAUSE OF THEIRAGRICULTURAL OPERATIONS, WHICH UTILIZE VOLUNTEER LABOR TO HELP SUBSIDIZE THE COST OF FRESH PRODUCEFOR PROGRAM PARTICIPANTS.

OKAVANGO FOREST INVENTORY ANGOLA

EPILEPSY RESEARCH PROGRAM IDEA DEVELOPMENT AWARD

CONTINUUM OF CARE PROGRAM

ARRA - CAPITAL IMPROVEMENT PROGRAM

BUILDING PEACE & RESILIENCE

CONTINUUM OF CARE PROGRAM

ENHANCING SERVICES TO VICTIMS OF DOMESTIC VIOLENCE AND VIOLENCE PREVENTION EDUCATION IN THE ORTHODOX AND IMMIGRANT JEWISH COMMUNITY IN THE NEW YORK

THE PURPOSE OF THIS AWARD IS TO PROVIDE NIGERIAN LAW ENFORCEMENT AGENCIES WITH INCREASED CAPABILITIES TO EFFECTIVELY ADDRESS THE COMPLEX AND EVOLVING NATURE OF EXPLOSIVE ORDNANCE THREATS THROUGHOUT NIGERIA AND IMPROVE SECURITY FOR CIVILIAN POPULATION.

TO CULTIVATE URBAN FARMING FOOD SECURITY ENHANCE HEALTHY NUTRITION OPTIONS WHERE LONG STANDING SOCIAL ECONOMIC AND ENVIRONMENTAL DIS PARITIES IMPACTED THE UNDERSERVED COMMUNITIES IN MISSISSIPPI

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

CONTINUUM OF CARE PROGRAM

SUPPORT FOR PMWRA VEHICLES AND RISING GLOBAL FUEL COSTS

THE GRANTS TO ENGAGE MEN AND BOYS AS ALLIES IN THE PREVENTION OF VIOLENCE AGAINST WOMEN AND GIRLS PROGRAM SUPPORTS PROJECTS THAT DEVELOP AND IMPLEMENT STRATEGIES THAT ENGAGE AND MOBILIZE MEN AND BOYS AT THE INDIVIDUAL, GROUP, RELATIONAL, AND SOCIETAL LEVELS TO PREVENT DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, STALKING, AND SEX TRAFFICKING.   THE GRANTEE AND PROJECT PARTNERS WILL IMPLEMENT A PROJECT ADDRESSING:  PURPOSE AREA 1: DEVELOP AND/OR IMPLEMENT PROGRAMMING TO RECRUIT AND TRAIN MEN AND BOYS TO SERVE AS ROLE MODELS, POSITIVE INFLUENCERS, CHANGE AGENTS, AND/OR MENTORS TO ADDRESS AND PREVENT DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, STALKING, OR SEX TRAFFICKING. PURPOSE AREA 2: INTEGRATE EDUCATION ON DOMESTIC VIOLENCE, DATING VIOLENCE, SEXUAL ASSAULT, STALKING, OR SEX TRAFFICKING INTO ESTABLISHED SUPPORT AND/OR ENRICHMENT PROGRAMS TO ASSIST MEN AND/OR BOYS IN DEVELOPING HEALTHY RELATIONSHIPS, CHALLENGING SOCIAL NORMS THAT SUPPORT VIOLENCE AGAINST WOMEN AND GIRLS, BECOMING ACTIVE BYSTANDERS, AND UNDERSTANDING THE INTERSECTION OF THESE CRIMES AND OTHER TYPES OF RELATED VIOLENCE.  THE PROJECT WILL: 1) ESTABLISH A COORDINATED COMMUNITY RESPONSE (CCR) TEAM TO OVERSEE AND GUIDE PROJECT ACTIVITIES; 2) COMPLETE A LIMITED COMMUNITY NEEDS ASSESSMENT AND DEVELOP A STRATEGIC PLAN THAT OUTLINES THE IMPLEMENTATION PHASE OF THE PROJECT; 3) PROVIDE CRISIS INTERVENTION FOR CHILDREN, YOUTH, AND COMMUNITY MEMBERS AT ALL EDUCATIONAL, OUTREACH, AND TRAINING EVENTS NOT SPECIFICALLY TARGETED TO FIRST RESPONDERS OR ALLIED PROFESSIONALS; 4) CROSS-TRAIN PROJECT STAFF, PARTNER ORGANIZATIONS/PROGRAMS, AND CCR TEAM MEMBERS TO EXPAND THEIR KNOWLEDGE AND SKILLS TO BETTER UNDERSTAND EACH OTHER’S ROLE(S) AS WELL AS IMPROVE THE PROJECT AND ACTIVITIES; AND 5) ENGAGE IN A PLANNING PHASE PRIOR TO PROJECT IMPLEMENTATION.

NOVEL, BIO-INSPIRED CHLORAMINE FOR INFECTION ERADICATION IN CHRONIC WOUNDS - PROJECT SUMMARY TOPICAL ANTISEPTICS ARE A KEY STRATEGY IN THE TREATMENT OF INFECTED DIABETIC FOOT ULCERS (DFUS) TO ENHANCE THE OPPORTUNITY TO REHABILITATE AND HEAL. DFUS CAN RESULT IN OSTEOMYELITIS OF THE FOOT AND AMPUTATION OF LOWER EXTREMITIES. HALOMINE, DOING BUSINESS AS AVANTGUARD, HAS DEVELOPED AVANTAMINE, A STABILIZED CHLORINE CONTAINING CHLORAMINE, THAT CREATES A NOVEL ACTIVE WITH RESIDUAL EFFICACY TO COMPETE IN THE ANTISEPTIC SPACE, PROVIDING EXCELLENT BROAD-SPECTRUM EFFICACY AND NO HISTORY OF RESISTANCE GENERATION. CHLORINE IS NATURALLY BIOCOMPATIBLE BIOCIDE COMPARED TO ALTERNATIVE CHEMISTRIES BECAUSE OUR BODIES ALREADY UTILIZE CHLORINE: NEUTROPHILS TAKE CHLORINE FROM SALT IN BODILY FLUIDS TO PRODUCE HYPOCHLOROUS ACID (HOCL) AS AN INTERMEDIARY BEFORE ULTIMATELY GENERATING TAURINE CHLORAMINE. GIVEN THE BIOCOMPATIBLE NATURE AND NATURALLY SKIN-COMPATIBLE PH COMPARED TO DAKINS SOLUTION, HOCL HAS RECENTLY BECOME POPULAR GENERALLY AT 0.033% OR LESS CONCENTRATION FOR WOUND CLEANING, BUT HOCL IS LIMITED BY STABILITY PREVENTING GENERAL USE AT CONCENTRATIONS THAT WOULD BE MOST EFFECTIVE. AVANTAMINE IS A COMBINATION OF AN N-HALAMINE CONTAINING MONOMER AND OTHER MONOMERS THAT IMPROVE SOLUBILITY IN WATER. KEY DIFFERENTIATORS ARE: AVANTAMINE IS BROAD SPECTRUM; THE MOLECULES ARE TOO LARGE FOR CELLULAR UPTAKE, REDUCING SYSTEMIC TOXICOLOGY RISK; NO RESISTANCE GENERATION; THE FORMULATION HAS SHOWN NO SKIN IRRITABILITY; CHLORINE IS A QUICK AND EFFICIENT ANTIMICROBIAL. THE PROPOSAL IS DESIGNED TO OPTIMIZE THE PRODUCT AGAINST BACTERIA FOUND IN DFUS TO DECREASE THE PERSISTENCE OF THE CHRONIC WOUNDS. TO THIS WE WILL: 1) EXAMINE EFFICACY AGAINST BACTERIA USING A PORCINE TISSUE SKIN MODEL TO UNDERSTAND THE PERFORMANCE WITH A MILESTONE OF A 3-4 LOG REDUCTION IN CFU; AND 2) EVALUATE IN AN IN VIVO PORCINE MODEL, WHICH IS THE MOST SIMILAR TO HUMANS FOR SKIN BEHAVIOR. THE GOAL IS TO SHOW IMPROVED EFFICACY OVER THE CURRENTLY MOST EFFECTIVE ANTISEPTICS.

NON-COATING ANTI-MICROBIAL, ANTI-HOST PROTEIN DEPOSITION, ANTI-INFLAMMATORY URINARY CATHETER - ABSTRACT: CATHETER-ASSOCIATED URINARY TRACT INFECTION (CAUTI) IS THE MOST COMMON TYPE OF HEALTHCARE-ASSOCIATED INFECTION, HOWEVER CURRENTLY THERE IS NO EFFECTIVE TECHNOLOGY TO ADDRESS THE PROBLEM. ANTIMICROBIAL (ANTI-BIOFILM) FUNCTIONALITY ON THE CATHETER SURFACE IS AN IMPORTANT FIELD THAT HAS GAINED A LOT OF ATTENTION; HOWEVER, COMMERCIAL APPLICATIONS ARE LIMITED DUE TO A LACK OF INFECTION CONTROL OUTCOMES (SILVER-HYDROGEL COATING) OR IRRITATION/DISCOMFORT (NITROFURAL) IN CLINICAL TRIALS. RECENT RESEARCH HAS NOW SHOWN THAT BIOFILM FORMATION IS CAUSED BY PROTEIN DEPOSITION WHICH WILL ALSO CAUSE INFLAMMATION AND IMMUNOREACTION. THEREFORE, THE NEXT GENERATION TECHNOLOGY NEEDS BOTH ANTIMICROBIAL FUNCTIONALITIES ALONG WITH ANTI-IMMUNOREACTION CAPABILITIES TO PRODUCE A COMPOUND EFFECT FOR INFECTION CONTROL. OUR COMPANY INVENTED A NEW CATEGORY OF POLYMER ADDITIVE PRODUCT (HALOADDTM) THAT CAN BE COST-EFFECTIVELY BLENDED INTO EXISTING SILICON RUBBER RESINS TO PRODUCE SILICONE URINARY CATHETERS THAT CAN PROVIDE MULTIPLE FUNCTIONS SUCH AS ANTIMICROBIAL, ANTI-PROTEIN ADHESION AND ANTI-INFLAMMATION. THIS PHASE I EFFORT IS GEARED TOWARDS ANSWERING SOME BASIC FEASIBILITY, EFFICACY, AND SAFETY QUESTIONS ABOUT THIS APPROACH USING BOTH IN VITRO AND IN VIVO TESTING METHODS. WE PROPOSE THREE SPECIFIC AIMS: 1) OPTIMIZE POLYMER SYNTHESIS AND BLENDING PARAMETERS TO DEVELOP HALOADD-BLENDED SILICONE RUBBER FORMULAS WITH MAXIMUM ANTIMICROBIAL AND ANTI-FOULING EFFICACY; 2) DETERMINE UROPATHOGEN ATTACHMENT PREVENTION, BIOCOMPATIBILITY, AND STABILITY OF HALOADD-BLENDED SILICONE TUBES; 3) DEMONSTRATE IN VIVO THAT HALOADD CATHETER PROVIDES MEASURABLE ANTI-INFLAMMATION AND ANTI-BIOFILM OUTCOMES IN A MOUSE INFECTION MODEL. SUCCESS WITH THIS PHASE I EFFORT WILL LAY THE GROUNDWORK FOR FDA CLEARANCE FOR HUMAN TRIALS.

FY 2020 EXPANDING CAPACITY FOR CORONAVIRUS TESTING (ECT)

EMERGENCY SURVEY AND CLEARANCE

STEPPING UP--A PARTNERSHIP TO PROMOTE OUTREACH AND EXPAND SERVICES TO UNDERSERVED VICTIMS OF SEXUAL ASSAULT IN THE ORTHODOX AND IMMIGRANT JEWISH COMM

SARAH''S VOICE - ENHANCING CULTURALLY AND LINGUISTICALLY SPECIFIC SERVICES TO VICTIMS OF DOMESTIC VIOLENCE IN THE BUKHARIAN, PERSIAN, AND ORTHODOX JE

THE OFFICE ON VIOLENCE AGAINST WOMEN (OVW) EMERGING ISSUES AND TRAINING AND TECHNICAL ASSISTANCE CALL FOR CONCEPT PAPERS (CALL FOR CONCEPT PAPERS) INVITEDINTERESTED ELIGIBLE ENTITIES TO PROPOSE PROJECTS THAT EXPLORE NEW AND EMERGING ISSUES AND TRAINING AND TECHNICAL ASSISTANCE PROJECTS ADDRESSING THE NEEDS AND CHALLENGES OF OVW GRANTEES, SUBGRANTEES, AND THE LARGER VIOLENCE AGAINST WOMEN FIELD. IN PARTICULAR, WITH THE PASSAGE OF THE VIOLENCE AGAINST WOMEN ACT REAUTHORIZATION ACT OF 2022 (VAWA 2022), PUB. L. NO. 117-103, DIV. W, 136 STAT. 49, 840-962, OVW SOUGHT TO IDENTIFY INNOVATIVE PROJECTS AND TECHNICAL ASSISTANCE THAT ADDRESS THE NEW AND REVISED PROGRAMS AND ISSUES INCLUDED IN VAWA 2022, AS WELL AS OTHER EMERGING ISSUES IN THE FIELDS OF SEXUAL ASSAULT, DOMESTIC VIOLENCE, DATING VIOLENCE, AND STALKING. SEE 34 U.S.C. 12291(B)(11) AND (16). OVW REVIEWED THE SUBMITTED CONCEPT PAPERS, SELECTED PROMISING PROJECTS IN EACH OF THE CALL FOR CONCEPT PAPERS PURPOSE AREAS, AND CONTACTED SELECTED APPLICANTS TO INVITE THEM TO SUBMIT A FULL APPLICATION FOR THEIR CONCEPT PAPER THROUGH THE CALL FOR CONCEPT PAPERS INVITATION TO APPLY SOLICITATION. WITH FUNDING THROUGH THE OVW FY 2023 EMERGING ISSUES AND TRAINING AND TECHNICAL ASSISTANCE CALL FOR CONCEPT PAPERS, SHALOM TASK FORCE (STF) WILL IMPLEMENT THE CONSENT IN OUR COMMUNITIES: CURRICULUM DEVELOPMENT AND TRAINING TO PROMOTE SAFE RELATIONSHIPS AND PREVENT DOMESTIC VIOLENCE AND SEXUAL ASSAULT PROJECT. THIS PROJECT WILL PROVIDE TRAINING AND TECHNICAL ASSISTANCE TO OVW GRANTEES, SUBGRANTEES, AND POTENTIAL GRANTEES AND SUBGRANTEES TO INCREASE THEIR CAPACITY TO PROVIDE SERVICES TO UNDERSERVED ORTHODOX JEWISH SURVIVORS OF DOMESTIC VIOLENCE AND SEXUAL ASSAULT. THE GOAL OF THE PROJECT IS TO RAISE AWARENESS AMONG VICTIM SERVICE PROVIDERS ABOUT THE UNIQUE NEEDS OF THE ORTHODOX JEWISH COMMUNITY SO THAT ORGANIZATIONS CAN DEVELOP AND IMPLEMENT EFFECTIVE AND CULTURALLY APPROPRIATE OUTREACH AND SERVICES. OVER THE COURSE OF THE PROJECT PERIOD, SHALOM TASK FORCE WILL: 1) PRESENT WEBINARS; 2) DEVELOP FACT SHEETS, RESOURCE MATERIALS, AND GUIDES; 3) PRESENT AT OVW AND NON-OVW CONFERENCES, INSTITUTES, AND/OR ROUNDTABLES; AND 4) PROVIDE ONGOING TA TO VICTIM SERVICE PROVIDERS. THIS AWARD SUPPORTS PURPOSE AREA 1: EMERGING ISSUES. THE TIMING FOR PERFORMANCE OF THIS AWARD IS 24 MONTHS FOR $300,000, ALL OF WHICH WILL BE AWARDED THROUGH OVW TECHNICAL ASSISTANCE FUNDING.

NOVEL, BIO-INSPIRED CHLORAMINE TO TREAT CUTANEOUS FUNGAL INFECTIONS WITHOUT RESISTANCE GENERATION POTENTIAL - PROJECT SUMMARY RESISTANCE DUE TO MUTATIONS IN FUNGI IS A RESULT OF WIDESPREAD USE OF ANTIFUNGALS, WHICH HAS LED TO AN INCREASE IN CHRONIC CASES, AND IS CONSIDERED AN INCREASING PUBLIC HEALTH BURDEN BY THE CDC. THE CDC RECENTLY FLAGGED ANTIFUNGAL RESISTANCE AS AN INCREASING THREAT IN THE US, PARTICULARLY WITH RESPECT TO RINGWORM. HALOMINE, DOING BUSINESS AS AVANTGUARD, HAS DEVELOPED A STABILIZED CHLORAMINE THAT CREATES A NOVEL ACTIVE WITH RESIDUAL EFFICACY TO SERVE AS AN ANTIFUNGAL, PROVIDING EXCELLENT BROAD-SPECTRUM EFFICACY AND NO HISTORY OF RESISTANCE GENERATION. OUR POLYMER IS A COMBINATION OF AN N-HALAMINE CONTAINING MONOMER AND OTHER MONOMERS THAT IMPROVE SOLUBILITY. KEY DIFFERENTIATORS ARE: CHLORINE IS BROAD SPECTRUM; THE MOLECULES ARE TOO LARGE FOR UPTAKE BY CELLS, REDUCING CELL DEATH; NO RESISTANCE GENERATION; THE FORMULATION HAS SHOWN NO SKIN IRRITABILITY; CHLORINE IS A QUICK AND EFFICIENT ANTIMICROBIAL. THE PROPOSAL IS DESIGNED TO OPTIMIZE THE PRODUCT AGAINST FUNGI THAT CAUSE TINEA (RINGWORM): 1) TEST THE MIC/MBC FOR A LARGER COHORT OF FUNGI, FOLLOWED BY INCORPORATION INTO A HYDROGEL FORMAT TO CONFIRM THE BROAD-EFFICACY OF THE COMPOUND. 2) THE RESULTING FORMULATIONS WILL BE EXAMINED FOR ABILITY TO REDUCE BIOFILMS IN VIVO IN A PORCINE MODEL AGAINST T. RUBRUM OR T. INTERDIGITALE. THESE RESULTS WILL BE COMPARED TO EFFICACY OF MICONAZOLE (MICONAZOLE 7 – 2%, TOPCARE), CLOTRIMAZOLE (CLOTRIMAZOLE CREAM - USP 1%, TOPCARE), AND AN UNTREATED CONTROL GROUP, WITH A MILESTONE OF IMPROVED PERFORMANCE AGAINST THE COMPETITION. 3) THE FORMULATIONS WILL UNDERGO SAFETY TESTING VIA AN ACUTE DERMAL IRRITATION PROCEDURE FOLLOWING OCSPP 870.2500/OECD 404 GUIDANCE.